International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

A Comprehensive Study Of Non-Alcoholic Fatty Liver Disorder Literature Review

Maged Naser [1], Mohamed M. Nasr [2], and Lamia H. Shehata [3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,
[2] Consultant of General and Endoscopic Surgery (MD, FRCS)
[3] Care National Hospital, Department of Radiology
Corresponding Author: Maged Naser

Abstract: The prevalence of non-alcoholic fatty liver disorder (NAFLD) spans approximately 25% globally. The rate of occurrence is on the rise due to escalating rates of obesity, type 2 diabetes, and the metabolic syndrome. It is anticipated that NAFLD will emerge as the primary cause of cirrhosis necessitating liver transplants in the upcoming decade. Nevertheless, cardiovascular ailments remain the leading cause of mortality, and only a small fraction of individuals will develop fibrosis and liver associated complications. Hence, it is crucial to identify patients with progressive disease using non-invasive fibrosis markers, which encompass serology based assess-ents (e.g., NAFLD Fibrosis Score and ELF test) and imaging techniques (e.g., transient elastography). This approach aims to pinpoint suitable candidates for refer-al to secondary care for further evaluations like liver biopsy and expert assistance. Adjustments in lifestyle and weight reduction continue to be the foundation of treatment, yet we are poised to embark on a new phase of hopeful pharmacological therapies for NASH and fibrosis.Keywords: Non-Alcoholic Fatty Liver Disease, Fibrosis, Diagnosis, Management, Liver Disease

Key Factors:

•MAFLD is a result of metabolic dysregulation resulting in extended fats deposition in the liver.

•MAFLD can expand in lean patients, and patients with metabolic chance factors ought to be screened.

•Screening for hepatic steatosis should be accomplished with abdominal ultrasonography; if available, additional assessment with liver elastography and non-invasive liver scores need to be taken into consideration.

•Control of MAFLD presently makes a speciality of weight loss, an advanced nutritional composition (similar to a Mediterranean weight loss plan composition) and increased bodily activity.

•There may be no current specific pharmacological remedy for MAFLD; however, there are numerous ongoing clinical trials.

I-Introduction

Non-alcoholic fatty liver ailment (NAFLD) is described through macro vesicular steatosis in ≥5% hepatocytes, in the absence of a secondary reason which include alcohol or drugs. It contains a spectrum of disease from non-alcoholic fatty liver (NAFL) via to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. NAFLD is now a main motive of chronic liver disease worldwide,(1) Yet public information of the disorder remains very restricted,(2) and the complications of cirrhosis are left out inside the public discourse at the countrywide weight problems epidemic. however, NAFLD is one of the fastest developing regions of liver research and the following decade have to witness a change inside the therapeutic alternatives available for these patients. This overview will summarise our current expertise of disorder mechanisms, but awareness on epidemiology and techniques to diagnosis and management.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

1.Epidemiology

The global occurrence of NAFLD is ready 25%, ranging from 13% in Africa to 23% in Europe and 32% inside the Middle East.(1) Geographical variant reflects acknowledged variations in incidence and severity of disease between one-of-a-kind ethnic groups, most notably a defensive impact of black ethnicity and conversely higher rates of NASH in Hispanic groups,(3) perhaps in element secondary to higher frequency of genetic chance variations (e.g. rs738409 in PNPLA3) related to NAFLD.(4) There is a near association with type 2 diabetes, imperative weight problems, dyslipidaemia and the metabolic syndrome, every with a respective prevalence of 23%, 41%, 69% and 43% in NAFLD. consequently, the burden of disorder has extended from 15% in 2005 to 25% in 2010 in parallel to rising rates of weight problems.(1)

Table 1

Risk factors for metabolic (dysfunction) associated fatty liver disease (5)
Major risk factors
Central adiposity, overweight/obesity, insulin resistance, type 2 diabetes, atherogenic dyslipidaemia, arterial hypertension, metabolic syndrome
Dietary factors (high-calorie diets rich in saturated fats and cholesterol, soft drinks high in fructose, highly processed foods)
Sedentary lifestyle/occupation/low level of physical activity
Sarcopenia
Disease associations
Cardiovascular disease
Cerebrovascular disease
Chronic kidney disease
Osteoporosis
Cancer
Cognitive changes
Hyperuricemia
Hypothyroidism
Polycystic ovarian syndrome
Hypopituitarism

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

Sleep apnoea syndrome
Polycythaemia
Gut dysbiosis

The most crucial predictor of negative outcomes in NAFLD is the presence of fibrosis, in preference to histological features of NASH.(6,7) there's a small increase in all-cause mortality even at very early fibrosis, which rises on a linear scale with progressive fibrosis degree. Early (F1) fibrosis isn't always related to a large significant in liver-associated mortality, however substantially this rises exponentially with increasing stage such that mortality rates from liver ailment with bridging fibrosis (F3) and cirrhosis (F4) are 7.92 (in step with 1000 person follow up vs degree 0 fibrosis) and 23.3 respectively.(8) The rate at which fibrosis develops is generally very slow in NAFLD, despite the fact that extra speedy in patients with NASH (7 years per fibrosis degree) than with-out NASH (14 years), confirming the importance of NASH inside the evolution of fibrosis.(9) threat elements for progressive sickness include age, growing BMI and diabetes.(10)

The most not common purpose of demise in sufferers with NAFLD is cardiovascular disease (40%). despite the fact that a commonplace set of threat elements make contributions to this, latest studies have additionally shown that NAFLD itself might also independently increase hazard of heart ailment,(11) even though as yet this has now not been integrated into cardiovascular threat-assessment tools.

A minority of sufferers with NAFLD will broaden complications of chronic liver sickness, such as 4–8% loss of life from the complications of cirrhosis and 1–5% from hepatocellular carcinoma (HCC).(1) however, the general range of patients with end-degree liver disorder caused by NAFLD is rapidly growing; there has been a 170% growth in cases of NASH at the transplant waiting list in USA. from 2004–13,(12) and the share of liver transplants for NASH increased from 1.2% in 2001 to 9.7% in 2009. it's miles consequently predicted that NASH turns into the main purpose of liver transplantation within the United States of America in the next decade.(13) furthermore, some studies have raised issues that NAFLD can also predispose patients to HCC even within the absence of cirrhosis, however similarly studies is required in the subject.(14)

2. Molecular physiology

the buildup of lipids in hepatocytes, a system called hepatic steatosis, is a multifactorial phenomenon concerning an imbalance amongst fatty acid uptake, synthesis, oxidation, and export. the subsequent sections describe the key molecular mechanisms contributing to this method and their relevance in MASLD (table 2).

Table 2.

Molecular mechanisms involved in MASLD pathogenesis. ↑ increase, ↓ decrease.

Molecular Mechanism	Key Processes and Players	Relevance to MASLD Progression
Dysregulated Lipid Metabolism	Excessive fatty acid uptake(CD36,FATP2), Enhanced de novo lipogenesis(SREBP1,	Central to hepatic steatosis; initiates lipid accumulation, leading to metabolic over

		FAS), impaired lipid export (MTTP, ApoB)	load
	Insulin Resistance and Hyperinsulinemia	Reduced AKT phosphorylation, increased SREBP1 activation, impaired glycogen synthesis	Amplifies Lipogenesis and reduces lipid oxidation, promoting steatosis and metabolic stress
	Mitochondrial Dysfunction and Oxidative Stress	Impaired β-oxidation (PPARα, ACSL5), reduced ATP production, increased ROS, mitophagy defects (BNIP3, p62)	Directly drives hepatocyte injury, apoptosis, and Fibrogenesis
	Chronic Inflammation	Kupffer cell activation, cytokine release (TNF-α, IL-6, CX3CL1), inflammasome activation (NLRP3)	Links metabolic dysfunction to liver fibrosis; perpetuates hepatocyte injury
	Endoplasmic Reticulum (ER) Stress	ATF4-VLDLR axis, SIRT1 downregulation, unfolded protein response (UPR)	Exacerbates lipid accumulation and inflammatory signaling
	Adipokine Dysregulation	↓ Adiponectin, FGF21; ↑ Leptin, Resistin, RBP4	Creates a pro-inflammatory, pro-fibrotic micro-environment in the liver
utor)	Gut Microbiota Dysbiosis	↑ Intestinal permeability, ↑ LPS, ↑ TLR4/NF-κB signaling	Triggers hepatic inflammation via gut–liver axis
ptibility)	Genetic Factors	PNPLA3 I148M, TM6SF2, MBOAT7	Genetic variants modify lipid

			handling, inflammation, and fibrosis risk
se Course)	Epigenetic Modifications	miR-33 (↓ mitochondrial function), hypermethylation of ND6 (mitochondrial DNA)	Shapes disease severity through regulation of lipid metabolism, inflammation, and fibrosis

2.1. Fatty Acid Uptake

Fatty acid transporters, together with Cluster Differentiation 36 (CD36) and Fatty Acid delivery Protein 2 (FATP2), regulate hepatic fatty acid uptake. CD36 facilitates triglyceride accumulation by promoting Sterol Regulatory Element-Binding Protein 1 (SREBP1) activation through its interaction with Insulin-induced Gene 2 (INSIG2) [15]. Conversely, FATP2, an insulin-stimulated protein, converts fatty acids into acyl-CoA, that's eventually applied in triglyceride synthesis [16]. indeed, Kupffer cells are answerable for growing the expression of CD36 in response to an excessive-fat eating regimen, highlighting their essential function within the law of lipid metabolism [17].

Every other key protein concerned in fatty acid uptake is the Peroxisome Proliferator-Activated Receptor Alpha (PPARα). As a transcription element, PPARα regulates genes associated with lipid uptake and metabolism, which includes Carnitine Palmitoyl transferase 1 (CPT1), Acyl-CoA Oxidase 1 (ACOX1), CD36, and Fatty Acid Binding Protein 1 (FABP1). those genes are crucial for the uptake, intracellular trafficking, and right distribution of lipids in the cellular, making sure their channeling into appropriate metabolic pathways [18].

Another study emphasizes Sirtuin 6 (SIRT6) as a terrible regulator of fatty acid uptake. Its deficiency promotes the expression of fatty acid transporters including CD36, FATP2, and FABP1, facilitating lipid access into hepatocytes and contributing to hepatic fats accumulation. This suggests that SIRT6 typically acts as a brake on immoderate lipid uptake in the liver, promoting an extra balanced metabolism. This effect is thought to arise through the repression of PPARγ, a transcription factor that regulates the expression of fatty acid transporter genes [19].

Fibroblast growth factor 21 (FGF21) seems to modulate fatty acid uptake through influencing the expression of CD36, a key transporter that enables lipid access into hepatocytes. This regulatory mechanism suggests that, under ordinary situations, FGF21 prevents excessive fatty acid absorption, thereby shielding the liver from unnecessary fat accumulation [20] .

Fatty Acid Uptake inside the Liver: Molecular Mechanisms in MASLD. Fatty acids are transported into the hepatocyte through CD36 and FATP2. SIRT6 impacts fatty acid uptake via regulating FGF21 and transporter expression. Within the nucleus, PPARα activates key lipid metabolism genes, which includes CPT1 (involved in mitochondrial fatty acid oxidation) and ACOX1 (associated with peroxisomal fatty acid oxidation). The mitochondria and lipid droplets are depicted as vital additives of lipid processing in hepatocytes.

METTL3 plays a crucial function in hepatic lipid homeostasis by performing as a negative regulator of immoderate lipid uptake. METTL3 represses the expression of CD36, thereby restricting fatty acid access into hepatocytes and stopping needless lipid

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

accumulation that might result in lipotoxicity. This regulation happens through epigenetic adjustments, as METTL3 associates with histone deacetylases HDAC1/2 to induce the deacetylation of H3K9 and H3K27 at the Cd36 promoter, decreasing its transcription. In phrases of lipid delivery, METTL3 in all likelihood contributes to a stability between lipid uptake, oxidation, and secretion inside the shape of lipoproteins [21].

2.2. Lipogenesis: Synthesis of recent Lipids

Lipogenesis is a pivotal manner in triglyceride accumulation, generally regulated through the transcription aspect SREBP1, which governs the expression of lipid synthesis-associated genes, consisting of Fatty Acid Synthase (FAS), Stearoyl-CoA Desaturase-1 (SCD-1), and Acetyl-CoA Carboxylase (ACC1). Upon activation via insulin and glucose, SREBP1 substantially enhances the quantity and size of lipid droplets in hepatocytes, thereby promoting lipid accumulation [22,23]. Furthermore, the enzyme N-Acetyltransferase 10 (NAT10) has been shown to stabilize SREBP1c mRNA via acetylation, which similarly amplifies the de novo lipogenesis and contributes to hepatic lipid accumulation [24].

In addition to SREBP1, other molecular markers, together with FAS, play a critical position in lipid synthesis and insulin resistance. FAS has emerged as a capacity biomarker for insulin resistance and type 2 diabetes [25]. Insulin resistance disrupts now not handiest lipid synthesis but also key insulin signaling pathways, such as protein kinase B (AKT) phosphorylation. under regular physiological situations, phosphorylated AKT inhibits Glycogen Synthase Kinase 3 Beta (GSK-3 β), thereby promoting glycogen synthesis and enhancing insulin sensitivity. but, in states of insulin resistance, AKT phosphorylation is impaired, leading to the chronic activation of GSK-3 β, which contributes to accelerated blood glucose ranges [26].

Curiously, the inhibition of GSK-3β has been proven to minimize lipotoxicity, underscoring its function in metabolic dysfunction [27]. While AKT fails to phosphorylate GSK-3β, the latter remains energetic, exacerbating lipotoxicity and further disrupting lipid metabolism and glucose regulation. those findings highlight the interconnected nature of insulin signaling, lipid metabolism, and glucose homeostasis, suggesting that healing strategies focused on these pathways should mitigate metabolic dysfunction.

In vitro research the use of primary human liver cultures and HepG2 cells have furnished extra insights into these mechanisms. those research validated that insulin-brought about de novo lipogenesis activates SREBP1, ATP Citrate Lyase (ACLY), and acetyl-CoA carboxylase alpha (ACCα), leading to the accumulation of lipid droplets in hepatocytes. This activation underscores the crucial function of SREBP1 in using the expression of enzymes essential for lipid synthesis and its next impact on metabolic health [15].

2.3. Fatty Acid Oxidation

Fatty acid oxidation serves as an essential mechanism for stopping lipid accumulation and keeping energy homeostasis. This system is broadly speaking regulated through Peroxisome Proliferator-Activated Receptor Alpha (PPARα), a nuclear transcription aspect that turns on genes involved in lipid oxidation throughout mitochondria, peroxisomes, and the endoplasmic reticulum [28]. By means of promoting the breakdown of fatty acids, PPARα plays a crucial function in lowering lipid accumulation and counterbalancing lipogenesis.

Similarly to its function in lipid metabolism, PPARα exerts great anti-inflammatory effects. It achieves this via in a roundabout way inhibiting nuclear aspect-kappa B (NF-κB), a key regulator of anti-inflammatory pathways. This twin function underscores the significance of PPARα interest in retaining each the metabolic and anti-inflammatory stability [29]. However, while the PPARα expression is epigenetically downregulated, along with via promoter hypermethylation, its protective results are faded. This downregulation exacerbates irritation, impairs lipid oxidation, and contributes to the improvement of metabolic dysfunction [30].

Every other key player in fatty acid oxidation is the protein long-Chain Acyl-CoA Synthetase family member 5 (ACSL5), which allows the activation and next oxidation of long-chain fatty acids. ACSL5 interest is regulated by Ubiquitin-precise Protease 29 (USP29), which prevents its degradation and guarantees its purposeful stability. however, a decrease in USP29 ranges, as found in hepatocytes exposed to excessive-fats diets, disrupts this regulatory mechanism. decreased USP29 results in impaired ACSL5 activity, which, in flip, worsens insulin resistance, promotes hepatic steatosis, and intensifies irritation [31].

These interconnected pathways highlight the importance of PPARα and ACSL5 in fatty acid oxidation and underscore their roles in retaining metabolic equilibrium. Their dysfunction not most effective impairs lipid metabolism however also amplifies anti-inflammatory and insulin resistance pathways, similarly traumatic metabolic disorders.

2.4. Secure storage of Lipid Droplets

The safe storage of triglycerides in lipid droplets is crucial for stopping lipotoxicity and preserving cellular homeostasis. Lipid droplets are stabilized by structural proteins such as Perilipin 2 (PLIN2) and Diacylglycerol Acyltransferase 2 (DGAT2), which are crucial for their formation and feature. DGAT2 catalyzes the very last step in triglyceride synthesis, a manner tightly regulated through insulin to make certain proper energy storage [32,33,34].

latest evidence shows that the transcription element p63, a member of the p53 own family, plays a pivotal function in lipid accumulation inside hepatocytes. mainly, the TAp63 isoform has been shown to set off lipid droplet formation in mouse models through inhibiting fatty acid oxidation. This inhibition is mediated via the upregulation of Autophagy-associated 3 (ATG3), a protein whose expression will increase in reaction to accelerated TAp63 tiers. considerably, TAp63 expression is significantly upregulated under high-fat weight loss plan situations, in addition driving lipid storage and metabolic dysregulation [35].

Further, Glutathione S-Transferase A1 (GSTA1) has emerged as an essential player in lipid droplet formation within hepatocytes. studies performed in cellular cultures and human tissue samples recognized with MASLD have found out that low levels of GSTA1 are associated with lipid and triglyceride accumulation. under everyday physiological conditions, GSTA1 promotes the degradation of Fatty Acid Binding Protein 1 (FABP1), thereby limiting fatty acid uptake and synthesis. however, reduced GSTA1 levels disrupt this regulatory mechanism, main to greater lipid accumulation and contributing to metabolic dysregulation [36].

Furthermore, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC1α) has been identifyed as a key regulator of mitochondrial feature and lipid metabolism. Intriguingly, PGC1α expression increases inside the intestines of mice fed a Western weight loss program, promoting lipid synthesis through the regulation of hepatic lipid metabolism. The focused deletion of PGC1α within the intestine notably reduces the expression of lipogenic genes, such as Srebp1c, Fasn, and Scd1, and protects against hepatic lipid accumulation. This protective impact is mediated through the modulation of the Liver X Receptor (LXR), a critical regulator of lipid and ldl cholesterol metabolism. These findings spotlight the have an impact on of intestinal PGC1α on hepatic lipid accumulation and its potential as a healing goal [37].

Lipid accumulation within the liver is likewise intently connected to irritation, with the chemokine C-X3-C Motif Ligand 1 (CX3CL1) and its receptor C-X3-C Motif Receptor 1 (CX3CR1) gambling key roles in macrophage migration and polarization. In mouse models, M1 macrophages and hepatic stellate cells have been diagnosed as primary expressors of CX3CL1 and CX3CR1, contributing to anti-inflammatory responses. Importantly, the absence of CX3CR1 shifts the balance toward the seasoned-anti-inflammatory C-C Motif Chemokine Ligand 2 (CCL2)/C-C Motif Chemokine Receptor 2 (CCR2) axis, which exacerbates macrophage infiltration and infection. This underscores the crucial position of CX3CL1/CX3CR1-mediated signaling as a counter-regulatory mechanism that limits immoderate inflammation and slows the development of MASH [38].

In conclusion, lipid droplet formation and storage are tightly regulated by way of a community of proteins and signaling pathways that make sure metabolic stability. The dysregulation of those mechanisms now not handiest contributes to lipid accumulation but additionally amplifies anti-inflammatory techniques, underscoring their relevance in the pathogenesis of metabolic problems.

2.5. Lipid Exportation

The Microsomal Triglyceride Transfer Protein (MTTP) performs an essential function in lipid metabolism by way of catalyzing the meeting of triglyceride-rich lipoproteins, which include very low-density lipoproteins (VLDL), in the liver. mostly positioned in the endoplasmic reticulum, MTTP capabilities as a lipid chaperone, facilitating the transfer of triglycerides, cholesterol, and phospholipids to apolipoproteins, including Apolipoprotein B-100 (ApoB-100) [39]. This procedure is vital for the formation of functional lipoprotein particles required to export lipids from the liver as VLDL [40].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

SIRT6 deacetylates ACSL5, a key enzyme in the activation of long-chain fatty acids, thereby facilitating its oxidation and preventing lipid accumulation inside the liver. On the molecular level, the transport and metabolism of lipids within the liver are regulated by diverse proteins and enzymes that control the stability between fatty acid availability, their storage as triglycerides, and their removal through oxidation or the secretion of VLDL. on this context, ACSL5 performs an important function inside the conversion of free fatty acids into acyl-CoA, facilitating their next metabolism. The deacetylation of ACSL5 by SIRT6 enhances its interest in fatty acid oxidation, thereby lowering hepatic lipid accumulation [41].

Transmembrane protein 41B (TMEM41B) helps the movement of phospholipids throughout the endoplasmic reticulum (ER) membrane bilayer, allowing the formation of lipoproteins that delivery lipids via the bloodstream. TMEM41B deficiency within the liver ends in an nearly complete elimination of plasma lipids due to the absence of mature lipoproteins in the ER, which satirically also turns on lipid synthesis inside the liver. VLDL and chylomicrons are assembled within the ER and Golgi earlier than being secreted into the circulation. on this process, TMEM41B performs an essential role in the motion of phospholipids from the cytoplasmic monolayer of the ER bilayer to the luminal monolayer, making sure the proper coating and stability of forming lipoproteins. additionally, TMEM41B interacts with Surfeit Locus Protein 4 and Apolipoprotein B (ApoB), a key structural component of lipoproteins, suggesting that TMEM41B is an critical regulator of lipoprotein meeting [42].

Apolipoprotein B is a key protein in the formation of very low-density lipoproteins inside the liver and chylomicrons within the intestine. In its full-length shape, ApoB-100 is vital for the secretion of VLDL and its conversion into LDL, whilst the truncated version, ApoB-48, participates inside the formation of chylomicrons inside the intestine. for the duration of VLDL synthesis within the liver, ApoB-100 associates with triglycerides and other lipids through its interaction with microsomal triglyceride switch protein. This interplay is crucial because it permits ApoB to fold effectively and stabilize with an adequate lipid load, stopping its untimely degradation within the ER. As soon as assembled, VLDL is secreted into the bloodstream, where its miles metabolized to form LDL, which transports cholesterol to cells. If ApoB-100 isn't always synthesized correctly or cannot engage with microsomal triglyceride transfer protein, as occurs in certain mutations, VLDL secretion is extensively reduced, leading to lipid accumulation within the liver [43].

Activating transcription factor 3 (ATF3), while overexpressed in hepatocytes, promotes hepatic uptake of HDL, inhibits intestinal absorption of fats and cholesterol, and enhances opposite cholesterol delivery in macrophages. these effects are finished through the induction of scavenger receptor class B type 1 and the repression of cholesterol 12α-hydroxylase, impacting bile acid synthesis and cholesterol excretion. ATF3 inside the liver is inhibited via hydrocortisone, a stress hormone, suggesting a link between continual strain and the regulation of lipid metabolism and atherosclerosis. The decreased ATF3 expression in the liver is related to improved plasma HDL levels, indicating that its downregulation can be associated with cholesterol accumulation in the blood. ATF3 regulates hepatic HDL uptake via its interplay with p53, a tumor suppressor that still regulates the induction of scavenger receptor class B type 1 expression. furthermore, ATF3 modulates lipid absorption in the intestine via its interaction with hepatic nuclear factor 4α, ensuing within the inhibition of cholesterol 12α-hydroxylase expression, thereby reducing cholic acid production and affecting bile acid reabsorption in the intestine [44].

2.6. Pathogenesis and development of MASLD/MASH

An increasing body of evidence demonstrates that people with MASLD and its modern shape, MASH, showcase massive changes in adipokine profiles as compared to wholesome people. Adipokines, which are bioactive molecules secreted typically with the aid of adipose tissue, play a crucial role within the pathogenesis of MASLD via influencing metabolic approaches, insulin sensitivity, and anti-inflammatory pathways within the liver. In weight problems, the manufacturing of pro inflammatory adipokines is markedly extended, contributing to a chronic state of low-grade irritation that quickens hepatic harm and fibrosis. but, now not all adipokines exert adverse effects; certain adipokines possess anti inflammatory properties and can counteract liver infection and metabolic dysfunction. The imbalance between pro- anti-inflammatory adipokines is now recognized as a key mechanism using the transition from hepatic steatosis to greater excessive types of liver disorder, together with MASH [45].

Among those, adiponectin has been proven to enhance fatty acid oxidation, increase insulin sensitivity, and suppress pro-anti-inflammatory cytokines through the activation of the AMPK/JNK/ERK1/2 pathway, whilst additionally lowering oxidative pressure

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

with the aid of reducing the malondialdehyde and NOX2 levels and enhancing mitochondrial characteristic through the upregulation of UCP2 [46,47]. In evaluation, leptin, despite its beneficial role in lipid mobilization, contributes to hepatic oxidative stress and Kupffer mobile activation beneath situations of metabolic disorder, fostering infection and fibrosis [48]. FGF21, an endocrine hormone secreted via each the liver and adipose tissue, exerts hepatoprotective effects by activating the AMPK-SIRT1 and PI3K/Akt pathways, improving antioxidant capacity, mitochondrial β-oxidation, and insulin sensitivity, even as additionally mitigating ER stress [49,50]. Different adipokines, including RBP4, promote hepatic steatosis through growing pro-anti-inflammatory cytokine launch, de novo lipogenesis, and mitochondrial lipid oxidation disorder [51,52], while irisin has shown protecting effects with the aid of alleviating oxidative strain, lowering lipid accumulation, and selling mitochondrial biogenesis [53,54]. Furthermore, chemerin, vaspin, and apelin exhibit anti-inflammatory, insulin-sensitizing, and anti-apoptotic effects [55,56,57], whereas resistin and visfatin make a contribution to insulin resistance, ER strain, and anti-inflammatory cytokine manufacturing, exacerbating hepatic damage [58,59]. Extra shielding roles were identified for IGF-1, adipsin, and omentin-1, which collectively reduce oxidative strain, enhance mitochondrial function, and suppress apoptosis [60,61,62]. Conversely, IL-6 has been implicated in promoting mitochondrial disorder and apoptosis, further accelerating MASLD progression [63]. This numerous purposeful spectrum highlights the difficult and regularly opposing roles of adipokines in shaping the pathophysiological landscape of MASLD and MASH.

2.7. Drivers of Liver injury and Fibrosis

Inflammation and oxidative strain are pivotal drivers inside the progression from MASLD to MASH, intricately linking metabolic dysregulation with immune responses and fibrogenesis. pro-anti-inflammatory cytokines, which includes CX3CL1 and interleukin (IL) , appreciably make a contribution to hepatocyte damage and fibrosis by activating each autocrine and paracrine signaling pathways. These pathways impair mitochondrial feature, promote lipid accumulation, and force the activation of hepatic stellate cells, perpetuating the fibrotic method [64]. Similarly, the downregulation of key regulatory proteins exacerbates irritation. as an instance, the reduced expression of Suppressor of Cytokine Signaling 2 (SOCS2) helps the activation of NF-κB and inflammasome pathways, even as faded ranges of Metallothionein-1B (MT1B) enhance pro-anti-inflammatory cytokine manufacturing and fibrosis through the Phosphoinositide 3-kinase (PI3K)/AKT signaling pathway [65,66].

Moreover, Kupffer cellular activation performs a crucial role in perpetuating infection. This system is mediated via mitochondrial DNA released from damaged hepatocytes, which engages the Toll-like receptor (TLR) and Stimulator of Interferon Genes (STING) signaling pathways [67]. Lipid overload and oxidative strain in addition exacerbate these anti-inflammatory cascades through generating accelerated levels of reactive oxygen species (ROS). Those ROS impair mitochondrial β-oxidation and deplete important antioxidants, along with mitochondrial glutathione, developing a feedback loop that exacerbates hepatic damage [68,69]. In experimental models of MASH, decreased glutathione degrees and extended lipid peroxidation have been found. significantly, caffeine management has proven protective effects by means of modulating the TLR4/Mitogen-activated protein kinase (MAPK) pathway, inhibiting Jun N-terminal kinase (JNK), extracellular sign-regulated kinase (ERK), and p38 activation. This intervention reduces the manufacturing of pro-anti-inflammatory cytokines, together with IL-17, IL-1β, and tumor necrosis factor-alpha (TNF-α), whilst also stopping inflammasome activation [70].

Proteins with anti-inflammatory and antioxidant properties, consisting of Fibronectin type III domain Containing Protein 4 (FNDC4) and glutathione peroxidase 7 (GPx7), play protective roles towards MASLD progression. however, their reduced expression exacerbates infection and oxidative pressure, accelerating disorder progression [71,72]. Moreover, lipotoxicity induced through a high-fat diet (HFD) contributes to hepatic stellate cell loss, triggering macrophage recruitment to catch up on the loss of Kupffer cells inside the poisonous microenvironment. The oxidative stress-related Chemokine-like receptor 1 (CMKLR1), is also downregulated in HFD-fed mice, ensuing in a MASH phenotype characterised with the aid of accelerated TNF-α and IL-6 levels, reduced superoxide dismutase (SOD) activity, and impaired autophagy. Intriguingly, chemerin management mitigates these effects by way of activating the Janus kinase (JAK)2/sign transducer and activator of transcription (STAT) 3 pathway, reducing infection and oxidative harm [73,74,75,76].

Moreover, the intestinal deletion of PGC1α has been shown to decrease inflammatory markers which include CCL2 and TNF-α, adding to the M1/M2 macrophage ratio, while also decreasing the TGF-β expression, a key activator of hepatic stellate cells [40].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

HFD models further emphasize the position of transcriptional regulators together with Fork head box protein O1 (FOXO1), yes-associated protein (YAP), and Neurogenic locus notch homolog protein 1 (NOTCH1). Those regulators drive inflammatory cascades via the cGAS-STING signaling pathway, promoting macrophage polarization, and improving cytokine release [77,78]. Together, those interconnected mechanisms spotlight the complex interplay among inflammatory and oxidative stress pathways in accelerating hepatic fibrosis and disorder, underscoring their relevance as ability healing objectives to mitigate the development of MASLD to MASH.

2.8. Mitochondrial disorder

Mitochondrial disorder plays a pivotal role within the development of MASLD and its advanced levels, together with MASH, as it's far pushed by metabolic stress, lipid overload, and irritation. below those situations, hepatocyte mitochondria end up beaten by the immoderate accumulation of lipids, main to impaired energy manufacturing, a discounted oxidative capability, and elevated ROS generation. consequently, this initiates a vicious cycle characterized by way of oxidative strain, lipid peroxidation, the discharge of inflammatory cytokines, and hepatocyte apoptosis. together, those processes exacerbate hepatic infection and fibrosis, further deriving ailment development [79]. Furthermore, compromised mitochondrial function manifests as faded ATP manufacturing, decreased basal and maximal respiratory capacity, and reduced energy reserves. additionally, the interest of β-hydroxyacyl-CoA dehydrogenase (β-HAD), a vital enzyme worried in β-oxidation, is drastically decreased, further impairing lipid metabolism and power homeostasis [80]. Those interconnected mechanisms highlight the crucial function of mitochondrial disorder within the pathogenesis of MASLD and its more intense forms.

Mitochondrial dysfunction is intricately connected to impaired autophagy and mitophagy, which can be important methods for keeping cell homeostasis. In lipid-overloaded hepatocytes, proteins which include DDX58 and TMEM55B, which modify autophagy and lysosomal trafficking, are significantly downregulated. This downregulation results in autophagic dysfunction, ensuing in the accumulation of damaged mitochondria and reported mitochondrial dysfunction [81,82]. Abnormalities in mitochondrial dynamics, together with a decreased expression in Dynamin-related protein 1 (Drp1) and Optic Atrophy 1 (OPA1), impair the critical procedures of mitochondrial fission and fusion. these disruptions contribute to the formation of megamitochondria which might be immune to mitophagy, further exacerbating mitochondrial dysfunction [83,84].

In HFD mouse models, mitochondria exhibited unusual morphologies, which includes the vacuolization and disorganization of mitochondrial cristae. Those alterations are related to a tremendous decrease in ATP stages, highlighting a failure within the cell power potential. moreover, the inhibition of mitophagy, a key manner for the elimination of damaged mitochondria, exacerbates this disorder. Proteins which include BCL2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) and p62, which are crucial for the law of mitophagy, display a reduced expression in hepatocytes tormented by MASLD/MASH, main to the accumulation of defective mitochondria and a growth in cell apoptosis [85].

Additionally, the protein Acylglycerol Kinase (AGK) is located to be decreased within the livers of sufferers with MASH, and its knockout in mice outcomes in MASH development. AGK is a subunit of the Translocase of the inner Mitochondrial Membrane 22 (TIM22) complex, answerable for the import of mitochondrial proteins into the internal membrane. AGK deficiency ends in the loss of mitochondrial cristae, a lower in ATP production, and impaired mitochondrial breathing [86].

Rising therapeutic interventions offer a few promise in mitigating these issues. as an example, the addition of FNDC4 or targeting proteins along with AGK, which is crucial for mitochondrial protein import and cristae integrity, has proven capability in assuaging mitochondrial disorder and partially restoring metabolic feature. however, in spite of these advances, accomplishing whole healing stays a big undertaking [71,86].

Together, those findings underscore the principal function of mitochondrial dysfunction in the development of MASLD and highlight the importance of growing therapeutic techniques that target restoring mitochondrial homeostasis.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

2.9. Endoplasmic Reticulum stress

Endoplasmic reticulum stress plays a pivotal function in exacerbating hepatic lipid accumulation and infection in MASLD. Especially, endoplasmic reticulum stress upregulates the expression of very-low-density lipoprotein receptors (VLDLRs) through a pathway mediated by means of Activating Transcription Factor 4 (ATF4), thereby promoting expanded lipid uptake and storage in hepatocytes. This procedure is similarly irritated by means of high fructose consumption, which no longer only elevates VLDLR levels however also reduces the expression of SIRT1, a protective regulator that mitigates steatosis. SIRT1 exerts its defensive effects by attenuating NF-κB signaling, thereby suppressing hepatic irritation and enhancing metabolic homeostasis [87].

Further to endoplasmic reticulum stress, intestine-microbiota-derived metabolites additionally contribute to hepatic lipid dysregulation. as an instance, metabolites like 3-hydroxyphenylacetic acid, produced through Phocaeicola vulgatus, indirectly modulate hepatic lipid accumulation by using inhibiting key enzymes worried in steroid synthesis. This highlights the complex interplay between gut microbiota and liver metabolism in MASLD [88].

Lipid overload further triggers massive inflammatory responses. studies on primary hepatocyte cultures subjected to lipotoxic pressure have validated that the elevated expression of Bromodomain-containing protein 4 (BRD4) complements the acetylation of histone H3 at lysine 27 within the promoter location of Gasdermin D. This epigenetic change, along with inflammasome activation, drives pyroptosis and the subsequent launch of pro-inflammatory cytokines, which include IL-1β, monocyte chemoattractant protein-1 (MCP-1), and TNF-α. The inflammatory cascade is amplified via the NLRP3 inflammasome, which interacts with heat shock protein 70 (Hsp70). This interaction helps the release of Hsp70 as a damage-associated molecular pattern (DAMP), which binds to TLR4 receptors on neighbouring hepatocytes. The binding turns on the NF-κB pathway, perpetuating a pro-inflammatory cascade that exacerbates liver injury [89].

Furthermore, lipotoxicity intensifies endoplasmic reticulum stress, which synergistically promotes each pyroptosis and NLRP3 inflammasome activation. This creates a vicious cycle of infection and hepatocyte damage, in addition contributing to the progression of MASLD. together, those interconnected mechanisms highlight the crucial function of endoplasmic reticulum stress, lipid overload, and intestine microbiota in driving the pathogenesis of MASLD [90].

2.10. Intestinal Microbiota Dysbiosis

The interaction among gut microbiota dysbiosis, lipopolysaccharides (LPS), and inflammatory pathways plays a pivotal position within the development of MASLD. An imbalance among bacterial phyla, inclusive of Verrucomicrobiae, Bacteroidetes, Proteobacteria, and Cyanobacteria, contributes to multiplied levels of LPS and pro-inflammatory cytokines including TNF-α and IL-6. those inflammatory mediators set off crucial signaling pathways, along with TLR4/NF-κB and AMPK, thereby promoting hepatic steatosis and inflammation. significantly, dysbiosis caused via a cocoa-paste-based food regimen has been shown to boom stages of Bacteroidetes, Proteobacteria, and Firmicutes, which correlate with MASLD, insulin resistance, and weight problems [91].

LPS, a robust endotoxin derived from intestine micro-organism, further exacerbates irritation through using IL-6 production through the TLR2/MyD88/IKKα/NF-κB pathway. This cascade amplifies the inflammatory reaction, contributing to the progression of liver harm and metabolic dysfunction [92,93].

Kupffer cells, the resident macrophages of the liver, are mainly touchy to adjustments within the gut microbiota. Upon exposure to increased levels of LPS, they polarize in the direction of the M1 pro-inflammatory phenotype, ensuing within the multiplied secretion of cytokines which include TNF-α, IL-1β, and IL-12, alongside ROS. This polarization extensively amplifies hepatic irritation and oxidative stress [94]. Furthermore, intestinal dysbiosis exacerbates this technique through growing the intestinal permeability. this is mediated, in component, by using the upregulation of serine-threonine kinase 39 (STK39), a poor regulator of intestinal barrier integrity, which facilitates the translocation of LPS into the systemic circulate [95].

LPS in addition amplifies inflammatory signaling via its interactions with downstream cytokine pathways. particularly, TNF-α induces NF-κB activation, while IL-6 triggers the JAK-STAT3 signaling pathway. IL-6 binds to its receptor and turns on JAK, which subsequently phosphorylates STAT3. The phosphorylated STAT3 translocates to the nucleus, enhancing the transcription of

genes that maintain irritation and metabolic disorder. This perpetual cycle of inflammatory signaling underscores the crucial position of the gut–liver axis in riding hepatic infection, steatosis, and the progression of MASLD [96].

Together, these findings spotlight the complex connections between gut microbiota dysbiosis, LPS-mediated signaling, and pro-inflammatory pathways, emphasizing their central function in the pathogenesis of MASLD.

2.11. Unraveling the Spleen–Liver Axis

The liver and spleen are physiologically interconnected, with spleen volume adjustments reflecting liver pathology because of portal hypertension and fibrosis progression.

Recent research spotlights the significance of spleen volume as a biomarker in liver disorder. Helgesson et al. analysed over 37,000 people the use of MRI and determined that spleen volume correlates positively with liver fat fraction, fibrosis rating, and liver volume. This looks at shows that spleen growth occurs early in MASLD development, doubtlessly because of expanded portal stress [97]. Moreover, volumetric assessments of the liver and spleen through CT and MRI have been proposed as reliable, non-invasive biomarkers for diagnosing and staging liver fibrosis. those measurements offer valuable prognostic records, surpassing traditional diagnostic procedures which include ultrasound [98].

The spleen–liver axis has been further elucidated through Zhang et al. (2023), who established that splenic CD11b + CD43hiLy6Clo monocytes exacerbate liver fibrosis. these cells migrate from the spleen into the fibrotic liver, wherein they differentiate into macrophages that activate hepatic stellate cells and promote fibrogenesis. single-cellular RNA sequencing identified these spleen-derived monocytes as key mediators of inflammation and fibrosis, revealing potential healing targets for controlling liver disease development [99]. Those findings underscore the clinical potential of spleen-derived biomarkers and immune cell modulation as novel techniques for early detection, tracking, and therapeutic intervention in liver fibrosis and cirrhosis.

2.12. Genetic and Epigenetic factors

Genetic and epigenetic elements play a considerable function within the pathogenesis and development of MASLD, highlighting their impact on lipid metabolism, mitochondrial feature, and fibrogenesis. among genetic determinants, the Patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M version is pivotal in promoting triglyceride accumulation. This mutation disrupts the dynamics between lipid droplets and the Golgi equipment, facilitating lipid accumulation and inducing proteomic changes related to infection. these changes underscore the crucial function of PNPLA3-I148M inside the development and progression of MASLD [100].

At the epigenetic front, microRNAs consisting of miR-33, embedded inside the SREBP2 gene, have emerged as crucial regulators in MASLD development. multiplied levels of miR-33 in each the liver and serum are strongly associated with impaired mitochondrial feature, disrupted lipid metabolism, and elevated fibrogenesis. Experimental research has demonstrated that the deletion of miR-33 substantially mitigates de novo lipogenesis, complements fatty acid oxidation, and improves mitochondrial dynamics by upregulating key metabolic regulators, which includes CPT1α, p.c.α, and AMPKα. those epigenetic interventions not best reduce lipid and cholesterol accumulation but also alleviate hepatocyte ballooning and decrease fibrosis markers including fibronectin, COL1A1, and hydroxyproline. moreover, the deletion of miR-33 promotes antifibrotic responses in hepatic stellate cells, underscoring its potential as a therapeutic goal [101].

Further to microRNA-mediated regulation, different epigenetic adjustments, including hypermethylation within the NADH dehydrogenase 6 (ND6) place of mitochondrial DNA, exacerbate mitochondrial dysfunction in MASLD. Hypermethylation disrupts the mitochondrial cristae shape, induces mitochondrial swelling, and ends in the basal hyperactivity of mitochondrial respiration, which collectively make contributions to lipid accumulation. furthermore, the hypermethylation of mitochondrial DNA affects the expression of nuclear genes concerned in lipid and bile acid metabolism, thereby intensifying metabolic and structural alterations in the mitochondria. those compounded consequences spotlight the difficult hyperlink among mitochondrial disorder and MASLD development [102].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

In summary, genetic elements which includes the PNPLA3-I148M variation, along epigenetic mechanisms including miR-33 and mitochondrial DNA hypermethylation, drive the metabolic, inflammatory, and fibrotic changes function of MASLD. These insights emphasize the significance of focused on both genetic and epigenetic pathways in developing effective therapeutic strategies [101,102].

Table 3.

Fibrosis score comparisons		
	NAFLD Fibrosis Score (NFS) (15)	Fibrosis-4 (FIB-4) score (14)
Parameters		
Age	Y	Y
AST	Y	Y
ALT	Y	Y
Platelet count	Y	Y
BMI	Y	N
Albumin	Y	N
Impaired fasting glucose/diabetes	Y	N
Calculation	–1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio – 0.013 × platelet count (× 109/L) – 0.66 × albumin (g/dL)	Age (years) × AST (U/L) ÷ platelets (109/L) × √ALT (U/L)
Results		
Rules out significant fibrosis	<–1.455	<1.3
Predicts significant fibrosis	>0.676	>3.25

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

Positive predictive value for significant fibrosis	82–90%	75%
Negative predictive value for significant fibrosis	88–93%	95%
ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; N, no; NAFLD, non-alcoholic fatty liver disease; Y, yes		

3. Clinical Manifestations

3.1. Early Stages of MASLD

MASLD has regularly been considered asymptomatic, in particular in its early levels. but, this doesn't suggest that people with the situation revel in no clinical manifestations or that the disease has no effect of lifestyles. research shows that many patients with MASLD document a spread of symptoms, even inside the absence of advanced fibrosis, which challenges the perception of MASLD as a silent disease [103,104,105].

MASLD commonly develops progressively over numerous years, frequently without causing apparent signs in its early levels. whilst lipids to start with begin to accumulate inside the liver, patients may be asymptomatic or present with very mild signs. This loss of overt clinical symptoms has earned MASLD the reputation of being a “silent disease”, as its sluggish progression often lets in the pathology to enhance undetected for prolonged periods [106]. The liver’s wonderful useful reserve capability similarly complicates the detection of MASLD. This capacity lets in the liver to hold highly normal feature no matter extensive cell harm, protecting signs and symptoms even in superior degrees together with fibrosis or cirrhosis. As an end result, diagnosing MASLD regularly becomes a vast task, with the disease regularly closing overlooked until considerable development has happened [103,106,107].

Whilst signs and symptoms are present, they are generally vague and nonspecific, including fatigue, soreness in the proper top quadrant of the stomach, and standard malaise. those symptoms can easily be misattributed to different conditions, in addition complicating the diagnostic method [106,107,108].

Biochemical markers can provide some perception into early MASLD, even though they're regularly inadequate for definitive analysis. as an instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, usually used to evaluate liver characteristic, may additionally remain inside everyday levels or show handiest slight elevations in early MASLD. that is because widespread inflammation or cellular damage, which would reason extra said adjustments in these enzymes, is not typically present at this level [108,109,110,111]. In addition, gamma-glutamyl transferase (GGT) ranges may be altered in MASLD however are more likely to be improved in superior levels with advanced stages of inflammation. Simple steatosis, a hallmark of early MASLD, is much less probable to bring about increased GGT levels [112]. Some other biochemical marker, alkaline phosphatase (ALP), that is discovered in numerous tissues, together with the liver, bones, and intestines, may imply liver or bile duct harm when increased. But, like GGT, ALP levels are greater usually increased in superior MASLD stages characterised with the aid of infection and fibrosis [112].

Even as MASLD frequently progresses silently, early-level signs and symptoms including fatigue and sleep disturbances, blended with subtle biochemical modifications, may also offer critical clues for its identification. recognizing these early manifestations is crucial for timely analysis and intervention, probably stopping the development to greater intense degrees of the sickness.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

3.2. The Silent progression of MASLD (MASH)

MASH, mainly in its early stages, is frequently seemed as a "silent" disorder because of its asymptomatic nature. however, numerous studies emphasize the important importance of early detection and effective management to prevent extreme headaches and enhance patients' high-quality of existence [113]. A number of the diverse pathological hallmarks of MASLD, fibrosis represents a pivotal turning factor within the sickness's natural records. that is because fibrosis is strongly related to an accelerated risk of complications and mortality [107,114].

The global burden of MASLD has escalated to epidemic proportions, with its occurrence growing constantly, especially in Western countries [115,116]. This growing prevalence, coupled with the ability for progression to extreme liver disorder, locations a good-sized pressure on healthcare structures. Therefore, early detection and the adoption of preventive strategies are vital for mitigating the growing demanding situations posed via this condition efficaciously.

Some other regularly mentioned symptom in MASH is pain inside the higher proper quadrant of the abdomen, which affects approximately 61% of sufferers. This pain is typically described as a persistent, dull pain which could radiate to the back. A few sufferers also revel in stomach distension, similarly impacting their day-by-day consolation and best of lifestyles [106,117]. Further, a generalized feel of malaise characterized via weak point, lack of appetite, and nausea may additionally emerge. Cognitive impairments, such as trouble concentrating and memory loss, also are commonplace in MASH. A study the usage of an animal model linked cognitive dysfunction and despair-like behavior to systemic irritation and neuroinflammation [119]. Those cognitive deficits can impair day by day functioning, stress social relationships, lessen temper, and increase anxiety degrees [106].

The early popularity of MASLD and T2D, coupled with a thorough knowledge of their complex interplay, is vital for enforcing timely and powerful interventions to halt sickness progression. robust evidence demonstrates that T2D exacerbates the improvement and development of MASLD, emphasizing the need for animal research to prioritize the competitive prevention and focused remedy of T2D as a key method for enhancing MASLD results [118]. Furthermore, by know-how the silent progression of MASH and its diverse clinical manifestations, healthcare carriers can decorate early analysis and set up tailor-made interventions. These measures are essential not most effective for improving affected person outcomes however additionally for assuaging the developing burden of MASH on healthcare structures.

3.3. Screening and Diagnostic technique for MASLD

Screening for MASLD is especially critical in sufferers with metabolic chance elements, which includes obesity, type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome. among these, people with type 2 diabetes are at particularly high threat, with an incidence accomplishing as much as 65% in this populace. Initial screening must encompass liver function tests (LFTs) and the calculation of the FIB-4 index, an extensively verified and easy tool for assessing fibrosis danger. But, FIB-4 has obstacles in more youthful patients underneath 35 years and older adults over 65 years, where it tends to underestimate or overestimate fibrosis threat, respectively. In some cases, opportunity rankings including the NAFLD Fibrosis scoring (NFS) or the Enhanced Liver Fibrosis (ELF) take a look at additionally offer additional value, in particular for intermediate-danger sufferers or while a better accuracy in detecting superior fibrosis is needed. Imaging also plays a vital position in MASLD assessment. Abdominal ultrasound, whilst useful for detecting hepatic steatosis, gives restrained application for fibrosis assessment. Consequently, elastography (including FibroScan) is desired in sufferers with expanded FIB-4 or suspected advanced fibrosis, as it affords a non-invasive estimate of liver stiffness [119]. In step with the 2024 EASL pointers, elastography is emphasized for fibrosis staging instead of relying on ultrasound alone. In select instances, liver biopsy is indicated whilst non-invasive checks yield conflicting results or if there may be medical suspicion of superior fibrosis, cirrhosis, or overlapping liver sicknesses. inside the diagnostic work-up for MASLD, extra assessments are essential to exclude different liver conditions that could coexist or mimic MASLD, consisting of hepatitis B and C panels, autoimmune liver ailment markers (ANA and ASMA), and iron studies to rule out hereditary hemochromatosis. This comprehensive approach, combining metabolic risk evaluation, non-invasive fibrosis evaluation, imaging, and laboratory testing, ensures an accurate prognosis and appropriate threat stratification for sufferers with suspected MASLD.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

4. Procedures to Manage MASLD

Intervening in MASLD all through its early degrees, whilst hepatic steatosis is the number one locating, is taken into consideration the most effective technique to managing the situation [118,120]. Early interventions not only increase the chance of stopping lengthy-time period complications but also make contributions to enhancing affected person fitness results [121,122].

life-style adjustments provide extra benefits by using addressing different additives of metabolic syndrome, consisting of dyslipidemia, high blood pressure, and insulin resistance. these improvements assist lessen the threat of cardiovascular disorder, a first-rate comorbidity in MASLD patients [123].

Nutritional adjustments play a vital function in dealing with MASLD. reducing the consumption of harmful meals and adopting a wholesome nutritional pattern, along with the Mediterranean diet, has been shown to offer tremendous advantages. This food regimen, characterised with the aid of its richness in fruits, vegetables, entire grains, and unsaturated fat, helps enhance hepatic steatosis, lessen systemic inflammation, and gradual the progression of the disease [117,120,123,124].

Weight reduction, carried out through an aggregate of dietary adjustments, bodily activity, or pharmacological treatments inclusive of semaglutide, has established profound impacts on MASLD control. Those interventions no longer best improve liver-related outcomes but also definitely have an effect on the pathophysiology of type 2 diabetes, as well as associated cardiovascular and renal complications, thereby addressing a couple of comorbidities simultaneously [107].

Moreover, nutrition E, a strong antioxidant, has proven promise in medical trials with the aid of decreasing hepatic steatosis and irritation, key drivers of MASLD development. This effect has been discovered often in non-diabetic patients [109].

Coffee is a wealthy source of bioactive compounds, consisting of caffeine, diterpenoid alcohols, potassium, niacin, and chlorogenic acid, which together exhibit antioxidant and antifibrotic properties. Those components make contributions to the protective consequences of coffee in opposition to liver-related metabolic and fibrotic situations. for instance, caffeine, a properly-studied coffee factor, has been proposed to save you or reverse liver fibrosis by performing as an adenosine A2A receptor antagonist, thereby inhibiting the activation of hepatic stellate cells—a key driver of fibrogenesis. additionally, chlorogenic acid and other polyphenols in Coffee make a contribution to its antioxidant properties, which assist mitigate oxidative pressure, a critical element in the development of liver diseases [125].

One of the lesser-recognized but large bioactive compounds in Coffee is N-methylpyridinium (NMP), an alkaloid discovered in coffee brew. At low concentrations (0.1–0.25 μM, equivalent to the quantity in a single to 3 espresso coffees), NMP has been shown to inhibit lipid accumulation in hepatic cells and reduce ROS levels. This impact is intently connected to the modulation of endoplasmic reticulum stress, a key player in lipid metabolism and oxidative pressure. Endoplasmic reticulum pressure activation promotes the upregulation of sterol regulatory detail-binding protein 1 (SREBP-1) and the expression of lipogenic genes, main to elevated lipid accumulation. Furthermore, endoplasmic reticulum stress induces ROS production in both the endoplasmic reticulum and mitochondria, exacerbating oxidative harm. NMP counteracts those outcomes through decreasing endoplasmic reticulum stress, as evidenced by means of the downregulation of endoplasmic reticulum pressure markers which include XBP1, ATF6, CHOP, GRP78, and P-eIF2α. by alleviating this stress, NMP restores normal stages of SREBP-1 and its lipogenic gene goals, thereby lowering lipid accumulation and diminishing ROS manufacturing, highlighting its antioxidant properties [126].

The protecting effects of coffee intake on liver health are further supported by using epidemiological evidence. A meta-analysis of seven research concerning 4825 coffee customers and 49,616 non-customers evaluated the connection between coffee intake starting from zero to over five cups according to day and metabolic-dysfunction-related steatotic liver disorder (MASLD). The findings revealed that consuming more than 3 cups of coffee every day is associated with a significantly decreased hazard of growing MASLD, in addition to liver fibrosis and cirrhosis [127]. Those findings align with current worldwide suggestions, which advise a daily intake of at least 3 cups of coffee, whether caffeinated or decaffeinated, for people without contraindications [113].

Then again, bariatric surgical procedure is a nicely-installed remedy for obesity that now not simplest promotes extensive weight loss but also improves metabolic syndrome and reduces hepatic fat accumulation, irritation, and fibrosis [128]. This surgical

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

intervention has proven awesome efficacy in addressing MASLD, in particular in people with morbid obesity or a high BMI followed by way of metabolic-syndrome-associated comorbidities. A retrospective study comparing the lengthy-time period consequences of bariatric surgical procedure located that, 5 years put up-surgery, 84% of patients (95% CI: 73.1–92.2%) finished the resolution of steatohepatitis without worsening fibrosis, while fibrosis itself reduced with the aid of 70.2% (95% CI: 56.6–81.6%) [129].

A number of the various bariatric procedures, the Roux-en-Y gastric skip (RYGB) has proven precise promise in improving fibrotic MASH. Particularly, RYGB resulted in a marked discount in the fibrotic NASH index (FNI) score, with 64% of patients identified with fibrotic MASH at baseline demonstrating widespread improvement put up-surgical operation. these effects align with previous findings by Pais et al., who pronounced that sufferers with high histological pastime grades experienced great improvements following bariatric surgery, which include an 80% decision rate of MASH [130].

Collectively, these findings underscore the capability of RYGB as an effective intervention for improving fibrotic MASH, specifically in patients with advanced sickness [131].

The regular evidence from those studies highlights the role of bariatric surgical procedure in addressing no longer simplest metabolic and weight-associated outcomes but also liver-specific pathologies. by using reducing hepatic fat, irritation, and fibrosis, bariatric surgical operation offers a promising therapeutic method for patients with MASLD and fibrotic MASH, mainly people with advanced ailment and obesity-related metabolic complications. those consequences emphasize the significance of considering bariatric surgical procedure as a possible treatment choice for people with severe liver ailment and weight problems, providing each metabolic and hepatic benefits.

4.1. Drugs Development for MASLD and MASH Treatment

4.1.1. Resmetirom

Resmetirom is the primary, and, presently, the only, FDA-permitted remedy for MASH with mild to advanced fibrosis. Its approval was granted in March 2024, marking a considerable milestone within the management of this condition [132,133,134].

This drug features as a selective agonist of the thyroid hormone receptor beta (THR-β), in particular concentrated on the liver. In MASH, the position of THR-β is impaired, main to reduced mitochondrial characteristic, diminished fatty acid β-oxidation, and an increase in fibrosis. Resmetirom without delay addresses those problems, restoring a number of the misplaced metabolic activities [137,138]. Via decreasing lipotoxicity and enhancing mitochondrial characteristic in hepatocytes, Resmetirom in all likelihood contributes to it found anti-inflammatory and antifibrotic effects. moreover, the medicine has established a high-quality impact on lipid profiles, particularly by way of lowering low-density lipoprotein (LDL) cholesterol levels. These blended advantages highlight its ability for comprehensive metabolic development in patients with MASH [134,136].

Although, like every medicine, Resmetirom is associated with a few aspect effects. The maximum mentioned unfavorable consequences consist of diarrhea and nausea, that are usually slight and self-limiting, and arise early inside the route of remedy. Importantly, clinical trials have proven that the drug does now not negatively affect heart charge or body weight, which similarly supports its protection profile [133,135]. Although Resmetirom has already obtained FDA approval, ongoing studies are targeted on comparing its long-time period consequences and determining its impact on clinical outcomes. These investigations aim to provide in addition insights into its efficacy and safety over extended durations of use [135,136].

Different drugs have now not but been accredited via the FDA and are nevertheless below research, which we can discuss later. we are able to also define their ability blessings in MASLD, in addition to their destructive results .

4.1.2. PPAR

PPARs are a group of nuclear receptors that play an important function in regulating lipid and glucose metabolism. Because of this essential function, they are taken into consideration attractive healing targets for MASLD and MASH. numerous tablets were evolved to goal these receptors. even as some act selectively on the α or γ subtypes, others exhibit dual pastime or act more extensively as agonists throughout all PPAR subtypes.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

One top notch drug is Pemafibrate, a selective PPAR-α modulator. Pemafibrate has validated a sizable capability to enhance lipid parameters and decrease ALT stages without inflicting an increasing in creatinine, which is a common problem with different remedies [137].

Then again, Saroglitazar targets both the α and γ isoforms, making it a dual PPAR-α/γ agonist. This drug has confirmed effective in treating atherogenic dyslipidemia, which regularly accompanies MASLD. Its mechanism of action consists of promoting fatty acid oxidation, decreasing VLDL production, and lowering apolipoprotein C-III levels. additionally, Saroglitazar induces the expression of PPAR-γ-sensitive genes concerned in carbohydrate and lipid metabolism. those results together lessen the hepatic metabolic load and improve glycemic manage [138].

finally, Pioglitazone, a PPAR-γ agonist, is a well-known hypoglycemic agent frequently used to treat T2D. however, it has additionally shown top notch blessings in MASLD and MASH [139].

clinical trials with Pioglitazone have verified its capacity to reduce hepatic fats content at the same time as appearing as an insulin sensitizer. enhancing insulin sensitivity enables alter blood glucose degrees, a crucial aspect in handling MASLD. moreover, Pioglitazone exerts additional metabolic blessings, such as reductions in triglycerides, LDL ldl cholesterol, and free fatty acids. because of these multifaceted effects, Pioglitazone is taken into consideration particular amongst antihyperglycemic agents for its potential to enhance liver histology in sufferers with MASH [139].

The improvement of drugs targeting PPARs gives a promising road for addressing the complex metabolic and histological modifications associated with MASLD and MASH. each drug reveals awesome mechanisms and blessings, offering a tailored method to dealing with these difficult situations.

4.1.3. SGLT2

Any other class of medicine is the sodium-glucose cotransporter (SGLT) inhibitors, that have proven numerous useful results, in particular in MASLD and MASH. Further to their number one use in treating MASLD, those drugs maintain promising ability for addressing multiple metabolic and hepatic abnormalities [140].

Selective SGLT2 inhibitors generally act at the kidneys via inhibiting glucose reabsorption in the renal tubules. This motion promotes glucose excretion through the urine, which finally lowers blood glucose degrees and improves insulin resistance [144]. Moreover, the excretion of glucose leads to weight reduction, a vital healing aim in MASLD management [141,142]. In addition to selective SGLT2 inhibitors, a few drug's goal both SGLT1, which blocks intestinal glucose absorption, and SGLT2 in the kidneys. This dual mechanism of action presents additional metabolic and hepatic benefits [143].

Similarly to these results, several studies have shown that SGLT2 inhibitors significantly reduce hepatic steatosis [140,141,143]. Curiously, this reduction has been discovered not best in sufferers with T2D however additionally in the ones without the circumstance [143]. Moreover, upgrades had been continually said in serum markers of liver damage, consisting of ALT, AST, and GGT, further assisting the liver-protecting outcomes of these capsules [141,143]. Some other noteworthy gain of SGLT2 inhibitors lies in their fine impact on lipid profiles. These capsules had been associated with reductions in triglyceride degrees and will increase in HDL cholesterol, which make a contribution to an progressed cardiovascular threat profile [144].

However, the effects of SGLT2 inhibitors on hepatic fibrosis continue to be a topic of dialogue. Even as some studies endorse that those drugs might also improve hepatic fibrosis in patients with MASH—as evidenced by means of decrease in liver stiffness measured by way of brief elastography—different research show a specific end result [140,143].

Licogliflozin is a dual SGLT1 and SGLT2 inhibitor. This drug has proven full-size reductions in hepatic steatosis and upgrades in liver enzyme levels, which include ALT, AST, and GGT. moreover, it has been associated with improvements in hepatic fibrosis markers. Despite the fact that licogliflozin has no longer proven widespread adjustments in plasma lipid levels or insulin resistance, it's been proven to lessen HbA1c levels, indicating its capability utility in glycemic control [143]. Examples of SGLT2 inhibitors that have been recognized as capability healing alternatives for MASLD and MASH due to their extensive-ranging benefits consist of dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, and ertugliflozin [140,143,145,146].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

4.1.4. FXR Agonist

Several drugs have been advanced to goal the farnesoid X receptor (FXR), either as standalone treatment options or in combination with other treatments. FXR is a nuclear receptor that plays a vital role in bile acid homeostasis, lipid and glucose metabolism, oxidative stress, and infection [147,150]. by using targeting FXR, these drugs goal to modulate metabolic pathways and deal with the underlying mechanisms of liver disorder. FXR agonists are drugs that bind to and activate FXR, triggering a cascade of metabolic outcomes that make a contribution to stepped forward liver function and reduced disease development.

Second-era FXR agonists, inclusive of Vonafexor, have been designed to spark off FXR in a more potent and selective manner. Research have established that Vonafexor correctly reduces hepatic steatosis and improves markers of liver harm. Moreover, it contributes to the management of MASLD by promoting weight loss and enhancing renal function. Dosing studies for Vonafexor have found out that doses of 100 mg and 200 mg consistent with day bring about widespread reductions in hepatic steatosis. In comparison, higher doses, which include 400 mg, do now not offer extra efficacy advantages and are related to an extended incidence of side consequences. those side outcomes, that are like those observed with different FXR agonists, include moderate pruritus and changes in lipid profiles [149].

Another promising FXR agonist underneath improvement is EDP-305. This drug has shown beneficial outcomes much like OCA, including reductions in C4 levels and improved fibroblast growth factor 19 (FGF19) levels. But, EDP-305 has the delivered gain of causing much less extensive will increase in LDL cholesterol as compared to OCA and other capsules in this magnificence, inclusive of Aldafermin. This difference may make it a more favorable alternative for sure affected person populations [149].

Cilofexor, every other FXR agonist, operates via a mechanism of movement just like other tablets on this class. whilst it stocks a few of the useful results of FXR agonists, it has been found to be less robust in lowering hepatic steatosis and ALT tiers [149]. despite the fact that, it remains a potential healing alternative because of its normal tolerability and safety profile.

By using focused on FXR, those capsules provide various advantages, consisting of advanced liver histology, metabolic regulation, and decreased liver-associated irritation. however, careful consideration of dosing and side consequences is crucial on the way to optimize their healing potential.

4.1.5. Obeticholic Acid

Obeticholic acid (OCA) has been drastically studied in patients with MASH and cirrhosis. it has been proven to reduce bile acid synthesis by way of reducing C4 levels (a precursor of bile acids) and increasing the stages of FGF19. Moreover, OCA exhibits extensive anti-inflammatory and anti-fibrotic results [150].

Clinical research has constantly validated that OCA improves liver histology through lowering fibrosis, inflammation, and cellular damage [147,151]. However, its use is associated with a few common place but reversible aspect outcomes, which includes pruritus, extended bile lithogenicity, and multiplied LDL levels of cholesterol.

4.1.6. GLP-1 Receptor Agonist

Glucagon-like peptide-1 (GLP-1) receptors are the target of numerous tablets, either as direct agonists or in aggregate with different medications. GLP-1, a hormone broadly speaking secreted with the aid of L cells inside the intestines, functions as an incretin. this indicates it promotes insulin secretion in reaction to glucose, thereby maintaining glucose ranges underneath manage via proportional insulin excretion. Importantly, GLP-1 receptors are widely allotted throughout the frame, which debts for the hormone's numerous non-glycemic effects. Similarly to its primary position in glucose regulation, GLP-1 receptor agonists provide several advantages, especially for sufferers with MASLD. A key advantage of these tablets is their ability to modify appetite and induce satiety, which, in flip, contributes to weight reduction. This impact is mediated via the modulation of gastric emptying, delaying the rate at which meals movements from the stomach to the small gut. Furthermore, GLP-1 receptor agonists definitely influence lipid metabolism, blood strain, and cardiovascular health, whilst also showing ability advantages for cognitive characteristic and mood [152]. Those extensive results make these drugs surprisingly effective for handling T2D and obesity, in which they have got lengthy been used as first-line remedies.

lately, but, research has increased their ability programs to MASLD, with promising consequences in lowering hepatic steatosis and enhancing typical metabolic feature [152]. some drugs currently underneath research for the remedy of MASLD and MASH include semaglutide, dulaglutide, liraglutide, exenatide, cotadutide, and beinaglutide [132,152,153,154,155,156,157].

GLP-1 receptor agonists have demonstrated sizeable reductions in hepatic steatosis, largely attributed to improvements in insulin sensitivity and decreased de novo lipogenesis [153,158]. Moreover, those drugs showcase anti-inflammatory properties, that are essential for mitigating hepatic inflammation a key issue of MASH pathophysiology. for instance, liraglutide has been shown to modulate the TLR4/NF-κB anti-inflammatory pathway, thereby decreasing liver damage [153].

Curiously, even though GLP-1 receptors aren't immediately expressed inside the liver, the useful outcomes of GLP-1 receptor agonists on hepatic function are notion to be primarily indirect. these include weight reduction, improved glycemic manipulate, and more suitable insulin sensitivity. though, emerging research suggest that these drugs might also have direct consequences on hepatocytes by using lowering lipogenesis and increasing fatty acid oxidation [153,158].

Further advancing this healing vicinity, dual agonists that focus on both GLP-1 and glucose-established insulinotropic peptide receptors, inclusive of tirzepatide, have proven more suitable efficacy in controlling glucose ranges and body weight in comparison to conventional GLP-1 receptor agonists. This dual mechanism of action allows for superior metabolic outcomes [159,160]. Moreover, dual agonists consisting of pemvidutide and survodutide, which target each GLP-1 and glucagon receptors, have validated big reductions in hepatic steatosis, liver stiffness, and biomarkers of liver fibrosis [160,161].

The improvement of triple receptor agonists, which simultaneously target GLP-1, glucose-dependent insulinotropic peptide, and glucagon receptors, represents a in-addition innovation on this field. superb examples consist of retatrutide and efocipegtrutide. Retatrutide has shown the ability to reduce hepatic steatosis, accompanied by means of changes in adiponectin, leptin, triglycerides, and FGF21 ranges elements carefully associated with lipid metabolism and insulin sensitivity. further, efocipegtrutide has validated reductions in hepatic steatosis, although it's far nonetheless in phase 2 trials for the treatment of MASH [160,162].

4.1.7. DPP-4

Dipeptidyl peptidase-4 (DPP-4) is an enzyme accountable for the degradation of incretin hormones, which include GLP-1 and the glucose-structured insulinotropic peptide. The inhibition of this enzyme effects in multiplied levels of incretins, which, in flip, complements insulin secretion and suppresses glucagon launch within the pancreas, thereby contributing to progressed glycemic manipulate [163]. Substantially, DPP-4 is broadly disbursed inside the liver and is overexpressed in MASLD. Moreover, serum levels of DPP-4 were shown to correlate with the severity of hepatic steatosis, suggesting a direct hyperlink among DPP-4 activity, liver damage, and hepatic lipogenesis [139,163].

Given the enzyme’s large role inside the pathophysiology of MASLD, DPP-4 inhibition represents a promising healing approach to prevent or postpone the progression of the sickness. This therapeutic capacity is in addition supported by using proof demonstrating that DPP-4 inhibitors can modulate anti-inflammatory pathways and fibrosis. Mainly, those drugs reduce the expression of pro-anti-inflammatory mediators, attenuate endoplasmic reticulum pressure, lower hepatocyte apoptosis, and lower the buildup of fibronectin and alpha-actin, key markers of fibrosis [163].

Numerous drugs within this class, which includes sitagliptin, vildagliptin, evogliptin, and saxagliptin, are generally used inside the treatment of T2D. But, latest studies have additionally explored their potential advantages in MASLD and MASH. These investigations have discovered that DPP-4 inhibitors can modulate fatty acid metabolism, reduce de novo lipogenesis, and improve hepatic glucose metabolism, thereby imparting potential therapeutic advantages for those liver situations [144,163,164].

4.1.8. FGF Analogs

Fibroblast Growth Factor (FGF)-21 is a hormone that performs a pivotal position in glucose and lipid metabolism, as well as in retaining power homeostasis. additionally, it regulates the secretion of adiponectin, an adipokine with multiple useful results, which include insulin-sensitizing, anti-steatotic, anti-inflammatory, and anti-fibrotic properties [165,166,167]. FGF-21 exerts its outcomes

by using enhancing the mitochondrial ability and activating the antioxidant pathways, thereby protecting cells from oxidative stress. Moreover, it helps save you hallmark capabilities of MASH, along with hepatocyte death, irritation, and fibrosis [167].

Despite those promising effects, the clinical utility of endogenous FGF-21 is restricted due to its short half-life, which restricts its therapeutic potential. To deal with this predicament, researchers have advanced long-acting FGF-21 analogs, inclusive of Pegbelfermin, Pegozafermin, and Efruxifermin [165]. although those analogs proportion comparable mechanisms of action, they fluctuate in their structural residences and pharmacokinetics. Pegbelfermin, as an instance, is conjugated with polyethylene glycol to extend its half-life's, allowing for weekly dosing. similarly, Pegozafermin is a glycopegylated, lengthy-acting analog that permits dosing durations of up to 2 weeks. In the meantime, Efruxifermin is composed of two covalently sure FGF-21 chains, which confer a better affinity for its receptors and decorate its healing efficacy [143,165,166].

In addition to FGF-21, FGF-19 has garnered attention for its wonderful metabolic capabilities.(167) FGF-19 in the main regulates bile acid metabolism but additionally offers advantages past glucose homeostasis. particularly, it reduces bile acid synthesis within the liver by using suppressing cholesterol 7α-hydroxylase (CYP7A1), a key enzyme in the bile acid synthesis pathway. Moreover, FGF-19 may also exert extra metabolic results via modulating the intestinal microbiome. Therapeutically, Aldafermin, an FGF-19 analog, has been evolved to harness these houses. Aldafermin has shown capability not simplest in regulating bile acid metabolism but additionally in improving liver health, especially in situations which include MASH. FGF-19 is also considered a marker of FXR activation, highlighting its capacity as a therapeutic goal for MASH treatment [168].

4.1.9. Statins

Rosuvastatin and atorvastatin belong to a set of medicines referred to as statins, extensively applied for cardiovascular risk decrease and improving the lipid profile in sufferers without or with liver diseases, which includes MASLD or MASH [169]. Beyond their cardiovascular advantages, research has tested their capacity to reduce lipid accumulation inside the liver. For instance, an observe discovered that rosuvastatin significantly reduced intrahepatic lipids through 42.3%, highlighting its ability role in addressing hepatic steatosis [170]. In certain cases, statins are used in mixture with other healing agents, consisting of FGF-19 analogs, to reap better lipid profile optimization and decorate affected person effects [168].

there are numerous different statins available in medical exercise, including simvastatin, pravastatin, lovastatin, fluvastatin, and pitavastatin. while a lot of these statins function by inhibiting HMG-CoA reductase, there are variations of their efficiency, in addition to differences of their destructive consequences and ability drug interactions. these variations make it beneficial to study their efficacy and protection in the context of MASLD or MASH [171].

4.1.10. Metformin

Metformin, a primary-line treatment for T2D, exerts its results frequently by way of enhancing insulin sensitivity in each peripheral tissues and the liver. past its glucose-reducing residences, metformin has been proven to inhibit hepatic gluconeogenesis and improve fatty acid metabolism, for that reason presenting metabolic advantages for the liver. A meta-evaluation found out that metformin may want to reduce ALT and AST tiers in patients with MASLD, similarly to reducing triglyceride and general cholesterol levels. moreover, metformin improves insulin resistance, which is a crucial mechanism underlying MASLD pathogenesis. In spite of those promising effects, the medical efficacy of metformin in MASLD and MASH remains a subject of debate. even as several research assist its healing blessings, others report restricted or no significant impact on the progression of these conditions [172].

4.1.11. Promising New medications

Further to statins and metformin, several rising therapies, some of which can be still under research, display promise as ability treatments for MASLD or MASH.

One such agent is Firsocostat, an inhibitor of acetyl-CoA carboxylase (ACC), a key enzyme involved in de novo lipogenesis. by means of inhibiting ACC, Firsocostat reduces hepatic lipid manufacturing, thereby decreasing hepatic steatosis. medical research has confirmed that Firsocostat is well-tolerated and efficiently reduces hepatic steatosis in patients with MASH. moreover, its

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

aggregate with other pills, consisting of semaglutide and cilofexor, has shown synergistic blessings, as those agents pathways in MASH pathogenesis. extensively, the mixture of semaglutide and Firsocostat has ended in more upgrades in hepatic steatosis and liver biochemistry as compared to semaglutide [150].

Aramchol, some other investigational drug, partly inhibits the expression of stearoyl-CoA desaturase 1 (SCD1), an enzyme worried in fatty acid synthesis. In preclinical models, Aramchol has been proven to lessen liver triglyceride content material and fibrosis. phase 2 scientific trials have further tested sizable decrease in hepatic steatosis, as assessed through magnetic resonance spectroscopy [173].

Selonsertib, an inhibitor of apoptosis signal-regulating kinase 1 (ASK1), targets pathways concerned in irritation and apoptosis, important factors of MASLD pathophysiology. While Selonsertib efficiently inhibited its target, medical trials failed to reveal the regression of fibrosis or the halting of disorder progression in MASH patients. however, the drug showed upgrades in the stronger liver fibrosis score and liver stiffness, as assessed with the aid of transient elastography [174].

Finally, PF-06835919, one of the maximum latest drug under investigation, has established the capacity to reduce hepatic steatosis in patients with MASLD and T2D. In addition to its results on liver fats, PF-06835919 has shown improvements in glucose stages, insulin sensitivity, and the homeostatic model evaluation of insulin resistance. even though in addition studies are required, this drug seems to keep big promise for treating MASLD and related conditions [175].

The panorama of MASLD/MASH remedy is swiftly evolving, with multiple promising remedies under investigation. future research focusing on combination remedies, biomarker discovery, personalised processes, and way of life modifications may be crucial in successfully managing this complicated ailment (table three).

Table 4.

5.Ongoing scientific trials.

Category	Treatment/Research	Mechanism/Target	Clinical Status/Research Goal
Thyroid Hormone Receptor Beta (THR-β) Agonists	Resmetirom (MGL-3196)	Liver-targeted THR-β agonist; reduces hepatic lipid content and fibrosis	Phase III (MAESTRO-NASH); evaluating efficacy in MASH patients with fibrosis
	VK2809	THR-β agonist; reduces liver fat content	Phase IIb; assessing efficacy in liver fat reduction
Fibroblast Growth Factor 21 (FGF21) Analogues	Efruxifermin (EFX)	FGF21 analogue; reverses liver fibrosis, improves insulin sensitivity	Phase IIb;showing fibrosis reversal, progressing to Phase III

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists	Semaglutide	GLP-1 receptor agonist; improves liver fibrosis, promotes weight loss	Phase III; Demonstrated improvement in fibrosis, seeking regulatory approval
Dual GLP-1 and Glucagon Receptor Agonists	Survodutide	Dual GLP-1 and glucagon receptor agonist; targets liver fibrosis and metabolic dysfunction	Phase III; received FDA Breakthrough Therapy designation
Stearoyl-CoA Desaturase-1 (SCD1) Inhibitors	Denifanstat	SCD1 inhibitor; reduces hepatic lipid accumulation and inflammation	Phase III;evaluating in non-cirrhotic MASH patients

Table 5. Experimental treatments in MASLD. ↑ increase, ↓ decrease.

Category	Treatment/Research	Mechanism/Target	Clinical Status/ Research Goal
Thyroid Hormone Receptor Beta (THR-β) Agonists	Resmetirom (MGL-3196)	Liver-targeted THR-β agonist; reduces hepatic lipid content and fibrosis	Phase III (MAESTRO-NASH); evaluating efficacy in MASH patients with fibrosis
	VK2809	THR-β agonist; reduces liver fat content	Phase IIb; assessing efficacy in liver fat reduction

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 52 No. 1 August 2025, pp. 296-335

Fibroblast Growth Factor 21 (FGF21) Analogues	Efruxifermin (EFX)	FGF21 analogue; reverses liver fibrosis, improves insulin sensitivity	Phase IIb;showing fibrosis reversal, progressing to Phase III
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists	Semaglutide	GLP-1 receptor agonist; improves liver fibrosis, promotes weight loss	Phase III; Demonstrated improvement in fibrosis, seeking regulatory approval
Dual GLP-1 and Glucagon Receptor Agonists	Survodutide	Dual GLP-1 and glucagon receptor agonist; targets liver fibrosis and metabolic dysfunction	Phase III; received FDA Breakthrough Therapy designation
Stearoyl-CoA Desaturase-1 (SCD1) Inhibitors	Denifanstat	SCD1 inhibitor; reduces hepatic lipid accumulation and inflammation	Phase III;evaluating in non-cirrhotic MASH patients

Abbreviations: THRβ, Thyroid hormone receptor-beta; PPAR, Peroxisome proliferator-activated receptor; SGLT2, Sodium-Glucose shipping Protein 2; FXR, Farnesoid X receptor; FGF, Fibroblast boom issue; DPP4, Dipeptidyl peptidase four; HMG-CoA, Hydroxymethylglutaryl coenzyme A; AMPK, AMP-activated protein kinase; GLP-1, Glucagon-like peptide 1; GIP, Gastric inhibitory polypeptide; ACC, Acetyl-Coenzyme A carboxylase; PDE, Phosphodiesterase; SCD1, Stearoyl-Coenzyme A desaturase 1; ASK1, Apoptosis signal-regulating kinase 1; MASH, Metabolic-disorder-related steatohepatitis; LDL, Low-density lipoprotein; VLDL, Very-low-density lipoprotein; HDL, high-density lipoprotein; TG, Triglycerides; ALT, Alanine transaminase; AST, Aspartate aminotransferase; GGT, Gamma-glutamyl transferase; ALP, Alkaline phosphatase; FPG, Fasting plasma glucose; eGFR, predicted glomerular filtration fee; HbA1c, Hemoglobin A1C; CRP, C-reactive protein; OSA, Obstructive sleep apnea; CKD, continual kidney sickness; AKI, acute kidney injury; UTIs, urinary tract infections. * Accepted with the aid of the FDA.

It is equally essential to manage comorbidities contributing to MASLD, inclusive of diabetes, hypertension, and dyslipidemia, through an included and affected person-focused method. A multidisciplinary crew, comprising healthcare specialists along with nutritionists, psychologists, and experts from diverse clinical fields, is crucial a good way to supply complete care tailor-made to every affected person's unique desires. Moreover, future techniques for the safe and powerful control of MASLD need to attention on addressing more than one pathophysiological objectives, including insulin resistance, irritation, oxidative strain, and fibrogenic

pathways, to mitigate disorder progression and enhance long-time period effects. This multifaceted method will not handily enhance patient care but additionally optimize the control of MASLD and its related comorbidities [120].

II- Conclusion

NAFLD is a unexpectedly developing reason of chronic liver ailment, mirroring the growing incidence of obesity and the metabolic syndrome. management requires a multidisciplinary method with clear hazard stratification. The healing alternatives for advanced disease stages will considerably enhance inside the subsequent decade.

Abbreviations

NAFLD	non-alcoholic fatty liver disease
MASLD	metabolic-dysfunction-associated steatotic liver disease
AASLD	American Association for the Study of Liver Diseases
EASL	European Association for the Study of the Liver
ALEH	Association Latinoamericana para El Estudio del Hígado
T2D	type 2 diabetes
BMI	body mass index
MASH	metabolic-dysfunction-associated steatohepatitis
NASH	non-alcoholic steatohepatitis
MetALD	metabolic alcoholic liver disease
CD36	Cluster Differentiation 36
FATP2	*Fatty Acid Transport Protein 2*
INSIG2	*Insulin-Induced Gene 2*
SREBP1	Sterol Regulatory Element-Binding Protein 1
FAS	Fatty Acid Synthase
SCD-1	Stearoyl-CoA Desaturase-1

ACC1	Acetyl-CoA Carboxylase
NAT10	N-Acetyltransferase 10
AKT	protein kinase B
GSK-3β	Glycogen Synthase Kinase 3 Beta
ACLY	ATP Citrate Lyase
ACCα	acetyl-CoA carboxylase alpha
PPAR	Peroxisome Proliferator-Activated Receptor
NF-κB	nuclear factor-kappa B
ACSL5	Acyl-CoA Synthetase Family Member 5
USP29	Ubiquitin-Specific Protease 29
PLIN2	Perilipin 2
DGAT2	Diacylglycerol Acyltransferase 2
ATG3	Autophagy-related 3
GSTA1	Glutathione S-Transferase A1
FABP1	Fatty Acid Binding Protein 1
PGC1α	Proliferator-Activated Receptor Gamma Coactivator 1-Alpha
LXR	Liver X Receptor
CX3CL1	C-X3-C Motif Ligand 1
CCL2	C-C Motif Chemokine Ligand 2
CCR2	Chemokine Receptor 2

MTTP	Microsomal Triglyceride Transfer Protein
VLDL	very low-density lipoproteins
TMEM41B	Transmembrane protein 41B
ER	Endoplasmic reticulum
ATF3	Activating transcription factor 3
IL	interleukin
SOCS2	Suppressor of Cytokine Signaling 2
MT1B	Metallothionein-1B
PI3K	Phosphoinositide 3-kinase
TLR	Toll-like receptor
STING	Stimulator of Interferon Genes
ROS	reactive oxygen species
MAPK	Mitogen-activated protein kinase
JNK	inhibiting Jun N-terminal kinase
ERK	extracellular signal-regulated kinase
TNF-α	tumor necrosis factor-alpha
FNDC4	Fibronectin Type III Domain Containing Protein 4
GPx7	glutathione peroxidase 7
HFD	high-fat diet
CMKLR1	Chemokine-like receptor 1

SOD	superoxide dismutase
JAK	Janus kinase
STAT	signal transducer and activator of transcription
FOXO1	Forkhead box protein O1
YAP	Yes-associated protein
NOTCH1	Neurogenic locus notch homolog protein 1
β-HAD	β-hydroxyacyl-CoA dehydrogenase
Drp1	Dynamin-related protein 1
OPA1	Optic Atrophy 1
AMPK	AMP-activated protein kinase
SIRT1	silent information regulator 1
BNIP3	BCL2/adenovirus E1B 19 kDa-interacting protein 3
TIM22	Translocase of the Inner Mitochondrial Membrane 22
VLDLR	very-low-density lipoprotein receptors
ATF4	Activating Transcription Factor 4
BRD4	Bromodomain-containing protein 4
MCP-1	monocyte chemoattractant protein-1
Hsp70	heat shock protein 70
DAMP	damage-associated molecular pattern
LPS	lipopolysaccharides

STK39	serine-threonine kinase 39
PNPLA3	Patatin-like phospholipase domain-containing protein 3
ND6	NADH dehydrogenase 6
ALT	alanine aminotransferase
AST	aspartate aminotransferase
GGT	gamma-glutamyl transferase
ALP	alkaline phosphatase
THR-β	thyroid hormone receptor beta
LDL	low-density lipoprotein
SGLT	sodium-glucose cotransporter
FXR	farnesoid X receptor
OCA	Obeticholic acid
FGF19	fibroblast growth factor 19
GLP-1	Glucagon-like peptide-1
DPP-4	Dipeptidyl peptidase-4
FGF	Fibroblast growth factor
CYP7A1	cholesterol 7α-hydroxylase
SCD1	stearoyl-CoA desaturase 1
THRβ	Thyroid hormone receptor-beta
SGLT2	Sodium-Glucose Transport Protein 2

DPP4	Dipeptidyl peptidase 4
HMG-CoA	Hydroxymethylglutaryl coenzyme A
GIP	Gastric inhibitory polypeptide
ACC	Acetyl-Coenzyme A carboxylase
PDE	Phosphodiesterase
ASK1	Apoptosis signal-regulating kinase 1
HDL	High-density lipoprotein
TG	Triglycerides
FPG	Fasting plasma glucose
eGFR	Estimated glomerular filtration rate
HbA1c	Hemoglobin A1C
CRP	C-reactive protein
OSA	Obstructive sleep apnea
CKD	chronic kidney disease
AKI	acute kidney injury
UTIs	urinary tract infections

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]- Younossi, Zobair M., et al. "Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes." Hepatology 64.1 (2016): 73-84.

[2]- Ghevariya, Vishal, et al. "Knowing what's out there: awareness of non-alcoholic fatty liver disease." Frontiers in Medicine 1 (2014): 4.

[3]- Bambha, Kiran, et al. "Ethnicity and nonalcoholic fatty liver disease." Hepatology 55.3 (2012): 769-780.

[4]- Romeo, Stefano, et al. "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease." Nature genetics 40.12 (2008): 1461-1465.

[5]- Eslam, Mohammed, et al. "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease." Hepatology international 14 (2020): 889-919.

[6]- Ekstedt, Mattias, et al. "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up." Hepatology 61.5 (2015): 1547-1554.

[7]- Angulo, Paul, et al. "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease." Gastroenterology 149.2 (2015): 389-397.

[8]- Dulai, Parambir S., et al. "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis." Hepatology 65.5 (2017): 1557-1565.

[9]- Singh, Siddharth, et al. "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies." Clinical gastroenterology and hepatology 13.4 (2015): 643-654.

[10]- Angulo, Paul, et al. "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD." Hepatology 45.4 (2007): 846-854.

[11]- Sinn, Dong Hyun, et al. "Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study." Gut 66.2 (2017): 323-329.

[12]- Wong, Robert J., et al. "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States." Gastroenterology 148.3 (2015): 547-555.

[13]- Charlton, Michael R., et al. "Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States." Gastroenterology 141.4 (2011): 1249-1253.

[14]- Mittal, Sahil, et al. "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease." Clinical Gastroenterology and Hepatology 14.1 (2016): 124-131.

[15]- Zeng, Han, et al. "CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing." Molecular metabolism 57 (2022): 101428.

[16]- Lu, Yang, et al. "HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation." Experimental Cell Research 430.1 (2023): 113721.

[17]- Blériot, Camille, et al. "A subset of Kupffer cells regulates metabolism through the expression of CD36." Immunity 54.9 (2021): 2101-2116.

[18]- Lee, Yo Han, et al. "Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA." Elife 10 (2021): e70472.

[19]- Nie, Kexin, et al. "Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake." Phytomedicine 111 (2023): 154661.

[20]- Dille, Matthias, et al. "Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1868.1 (2022): 166286.

[21]- Li, Xinzhi, et al. "The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression." Nature communications 12.1 (2021): 7213.

[22]- Sozen, Erdi, et al. "Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis." Metabolism Open 12 (2021): 100138.

[23]- Zhu, Chaoyu, et al. "SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1867.12 (2021): 166249.

[24]- Yang, Yanying, et al. "Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10." Molecular Metabolism 89 (2024): 102030.

[25]- Li, Yan-Ling, et al. "Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of m6A Modification." Nutrients 15.8 (2023): 1839.

[26]- Zywno, Hubert, et al. "The influence of coumestrol on sphingolipid signaling pathway and insulin resistance development in primary rat hepatocytes." Biomolecules 11.2 (2021): 268.

[27]- Khoury, Mireille, et al. "Glycogen synthase kinase 3 activity enhances liver inflammation in MASH." JHEP Reports 6.6 (2024): 101073.

[28]- Li, Xiao-Yun, et al. "Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease." World Journal of Hepatology 14.7 (2022): 1365.

[29]- Theys, Claudia, et al. "Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)." Frontiers in molecular medicine 3 (2024): 1283170.

[30]- Régnier, Marion, et al. "Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity." Scientific reports 10.1 (2020): 6489.

[31]- Hu, Sha, et al. "USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination." Clinical and Molecular Hepatology 31.1 (2024): 147.

[32]- Moliterni, Camilla, et al. "Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells." Journal of Lipid Research 65.12 (2024): 100692.

[33]- Selvaraj, Rajakumar, et al. "Preferential lipolysis of DGAT1 over DGAT2 generated triacylglycerol in Huh7 hepatocytes." Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1868.10 (2023): 159376.

[34]- Rong, Shunxing, et al. "DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER." Cell metabolism 36.3 (2024): 617-629.

[35]- Lima, Nátalia da Silva, et al. "Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function."

[36]- Jiang, Jing, et al. "Upregulation of hepatic glutathione s-transferase alpha 1 ameliorates metabolic dysfunction-associated steatosis by degrading fatty acid binding protein 1." International Journal of Molecular Sciences 25.10 (2024): 5086.

[37]- Piccinin, Elena, et al. "Intestinal Pgc1α ablation protects from liver steatosis and fibrosis." JHEP Reports 5.11 (2023): 100853.

[38]- Ni, Yinhua, et al. "CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status." Metabolism 136 (2022): 155272.

[39]- Yang, Wei, et al. "Regulation of cholesterol metabolism during high fatty acid–induced lipid deposition in calf hepatocytes." Journal of Dairy Science 106.8 (2023): 5835-5852.

[40]- Chen, Zhouji, et al. "Conditional hepatocyte ablation of PDIA1 uncovers indispensable roles in both APOB and MTTP folding to support VLDL secretion." Molecular Metabolism 80 (2024): 101874.

[41]- Hou, Tianyun, et al. "Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation." Molecular Cell 82.21 (2022): 4099-4115.

[42]- Huang, Dong, et al. "TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis." Cell metabolism 33.8 (2021): 1655-1670.

[43]- Strøm, Thea Bismo, et al. "Missense mutation Q384K in the APOB gene affecting the large lipid transfer module of apoB reduces the secretion of apoB-100 in the liver without reducing the secretion of apoB-48 in the intestine." Journal of Clinical Lipidology 17.6 (2023): 800-807.

[44]- Xu, Yanyong, et al. "Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism." Nature metabolism 3.1 (2021): 59-74.

[45]- Zhao, Ke, et al. "Adipokines regulate the development and progression of MASLD through organellar oxidative stress." Hepatology Communications 9.2 (2025): e0639.

[46]- Dong, Zhixia, et al. "Adiponectin inhibits NLRP3 inflammasome activation in nonalcoholic steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways." Frontiers in medicine 7 (2020): 546445.

[47]- Zhou, Mingyan, et al. "Upregulation of UCP2 by adiponectin: the involvement of mitochondrial superoxide and hnRNP K." PloS one 7.2 (2012): e32349.

[48]- Chatterjee, Saurabh, et al. "Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis." Journal of hepatology 58.4 (2013): 778-784.

[49]- Chau, Mary DL, et al. "Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway." Proceedings of the National Academy of Sciences 107.28 (2010): 12553-12558.

[50]- Yu, Yinhang, et al. "Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways." Molecular and cellular biochemistry 403 (2015): 287-299.

[51]- Liu, Yan, et al. "Retinol-binding protein 4 induces hepatic mitochondrial dysfunction and promotes hepatic steatosis." The Journal of Clinical Endocrinology & Metabolism 101.11 (2016): 4338-4348.

[52]- Yao, Jin-Mei, et al. "Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells." Free Radical Biology and Medicine 195 (2023): 58-73.

[53]- Park, Min-Jung, et al. "New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro." Cellular signalling 27.9 (2015): 1831-1839.

[54]- Batirel, Saime, et al. "The effect of Irisin on antioxidant system in liver." Free Radic Biol Med 75.Suppl 1 (2014): S16.

[55]- Pohl, Rebekka, et al. "Chemerin overexpression in the liver protects against inflammation in experimental non-alcoholic steatohepatitis." Biomedicines 10.1 (2022): 132.

[56]- Nakatsuka, Atsuko, et al. "Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex." Diabetes 61.11 (2012): 2823-2832.

[57]- Li, Cheng, et al. "The role of apelin–APJ system in diabetes and obesity." Frontiers in endocrinology 13 (2022): 820002.

[58]- Han, Dongli, et al. "Serum resistin levels in adult patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis." Journal of Clinical and Translational Hepatology 9.4 (2021): 484.

[59]- Heo, Yu Jung, et al. "Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes." Journal of diabetes research 2019.1 (2019): 4021623.

[60]- de la Garza, Rocio G., et al. "Insulin-like growth factor-1 deficiency and cirrhosis establishment." Journal of clinical medicine research 9.4 (2017): 233.

[61]- Lee, Eunjung, et al. "Stachydrine derived from fermented rice prevents diet-induced obesity by regulating adipsin and endoplasmic reticulum homeostasis." The Journal of nutritional biochemistry 107 (2022): 109036.

[62]- Gu, Naibing, et al. "The effects of intelectin-1 on antioxidant and angiogenesis in HUVECs exposed to oxygen glucose deprivation." Frontiers in Neurology 10 (2019): 383.

[63]- Skuratovskaia, Daria, et al. "IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and type 2 diabetes." International Journal of Molecular Sciences 22.4 (2021): 1774.

[64]- Dong, Jinrui, et al. "Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH." Nature communications 12.1 (2021): 66.

[65]- Li, Shuo, et al. "SOCS2 suppresses inflammation and apoptosis during NASH progression through limiting NF-κB activation in macrophages." International Journal of Biological Sciences 17.15 (2021): 4165.

[66]- Guan, Canghai, et al. "Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway." Journal of Lipid Research 66.1 (2025): 100701.

[67]- Yu, Yongsheng, et al. "STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis." The Journal of clinical investigation 129.2 (2019): 546-555.

[68]- Wu, Yue, et al. "Oxidative stress linked organ lipid hydroperoxidation and dysregulation in mouse model of nonalcoholic steatohepatitis: Revealed by lipidomic profiling of liver and kidney." Antioxidants 10.10 (2021): 1602.

[69]- Rauchbach, Einat, et al. "Cholesterol induces oxidative stress, mitochondrial damage and death in hepatic stellate cells to mitigate liver fibrosis in mice model of NASH." Antioxidants 11.3 (2022): 536.

[70]- Vargas-Pozada, Eduardo E., et al. "Caffeine inhibits NLRP3 inflammasome activation by downregulating TLR4/MAPK/NF-κB signaling pathway in an experimental NASH model." International Journal of Molecular Sciences 23.17 (2022): 9954.

[71]- Neira, Gabriela, et al. "FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease." Clinical Nutrition 43.9 (2024): 2221-2233.

[72]- Kim, Hyeon Ju, et al. "GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress." BMB reports 53.6 (2020): 317.

[73]- An, Xiuqin, et al. "Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway." Peptides 135 (2021): 170422.

[74]- Remmerie, Anneleen, et al. "Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver." Immunity 53.3 (2020): 641-657.

[75]- Seidman, Jason S., et al. "Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis." Immunity 52.6 (2020): 1057-1074.

[76]- Tran, Sophie, et al. "Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis." Immunity 53.3 (2020): 627-640.

[77]- Xu, Dongwei, et al. "The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression." Experimental & molecular medicine 56.8 (2024): 1843-1855.

[78]- Song, Kyoungsub, et al. "Yes-Associated protein in Kupffer cells enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis." Hepatology 72.1 (2020): 72-87.

[79]- Ajaz, Saima, et al. "Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)." Mitochondrion 57 (2021): 119-130.

[80]- Moore, Mary P., et al. "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD." Hepatology 76.5 (2022): 1452-1465.

[81]- Frietze, Karla K., et al. "Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death." Autophagy 18.1 (2022): 142-160.

[82]- Qin, Yuanyuan, et al. "Loss of TMEM55B modulates lipid metabolism through dysregulated lipophagy and mitochondrial function." bioRxiv (2024): 2024-11.

[83]- Steffen, Janos, et al. "The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR." Molecular Metabolism 64 (2022): 101566.

[84]- Yamada, Tatsuya, et al. "Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver." Iscience 25.4 (2022).

[85]- Chen, Mingtai, et al. "A classical herbal formula alleviates high-fat diet induced nonalcoholic steatohepatitis (NASH) via targeting mitophagy to rehabilitate dysfunctional mitochondria, validated by UPLC-HRMS identification combined with in vivo experiment." Biomedicine & Pharmacotherapy 168 (2023): 115831.

[86]- Ding, Nan, et al. "AGK regulates the progression to NASH by affecting mitochondria complex I function." Theranostics 12.7 (2022): 3237.

[87]- Peyman, Mona, et al. "SIRT1 regulates hepatic vldlr levels." Cell Communication and Signaling 22.1 (2024): 297.

[88]- Jin, Shengxi, et al. "Phocaeicola vulgatus alleviates diet-induced metabolic dysfunction-associated steatotic liver disease progression by downregulating histone acetylation level via 3-HPAA." Gut Microbes 16.1 (2024): 2309683.

[89]- Roy, Subhajit, et al. "Hepatic NLRP3-Derived Hsp70 binding to TLR4 mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a second hit." International journal of molecular sciences 24.22 (2023): 16354.

[90]- Zeng, Xin, et al. "Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis." Nutrition & metabolism 17.1 (2020): 11.

[91]- Kochumon, Shihab, et al. "Gut dysbiosis shaped by cocoa butter-based sucrose-free HFD leads to steatohepatitis, and insulin resistance in mice." Nutrients 16.12 (2024): 1929.

[92]- Zhang, Liting, et al. "TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells." Annals of Translational Medicine 9.18 (2021): 1429.

[93]- Didenko, V. I., et al. "Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases." Regulatory Mechanisms in Biosystems 13.1 (2022): 3-9.

[94]- Yin, Yue, et al. "Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization." Journal of cellular physiology 236.7 (2021): 5121-5133.

[95]- Xu, Qing, et al. "Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier." BioScience Trends 18.3 (2024): 289-302.

[96]- Sarkar, Ankita, et al. "Butyrate limits inflammatory macrophage niche in NASH." Cell death & disease 14.5 (2023): 332.

[97]- Helgesson, Samuel, et al. "Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis." Heliyon 10.8 (2024).

[98]- Kutaiba, Numan, et al. "The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review." Insights into Imaging 15.1 (2024): 146.

[99]- Zhang, Shaoying, et al. "CD11b+ CD43hiLy6Clo splenocyte-derived macrophages exacerbate liver fibrosis via spleen–liver axis." Hepatology 77.5 (2023): 1612-1629.

[100]- Sherman, David J., et al. "The fatty liver disease–causing protein PNPLA3-I148M alters lipid droplet–Golgi dynamics." Proceedings of the National Academy of Sciences 121.18 (2024): e2318619121.

[101]- Fernández-Tussy, Pablo, et al. "miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression." JCI insight 9.19 (2024): e168476.

[102]- Theys, Claudia, et al. "Mitochondrial GpC and CpG DNA hypermethylation cause metabolic stress-induced mitophagy and cholestophagy." International journal of molecular sciences 24.22 (2023): 16412.

[103]- Younossi, Zobair M., et al. "Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes." Hepatology Communications 4.11 (2020): 1637-1650.

[104]- Younossi, Zobair M., et al. "The potential role of fatigue in identifying patients with NASH and advanced fibrosis who experience disease progression." Clinical Gastroenterology and Hepatology 21.4 (2023): 970-977.

[105]- Vidal-Cevallos, Paulina, et al. "Occult liver disease: a multinational perspective." Annals of Hepatology 29.3 (2024): 101480.

[106]- Doward, Lynda C., et al. "Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study." The Patient-Patient-Centered Outcomes Research 14.5 (2021): 533-543.

[107]- Bandyopadhyay, Sanjay, et al. "Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 17.10 (2023): 102849.

[108]- Younossi, Zobair M., et al. "The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from National Health and nutrition examination survey (NHANES) 2005-2010 and 2017-2018." Liver Int (2022).

[109]- Lee, Han Ah, Hye Ah Lee, and Hwi Young Kim. "Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms." Scientific Reports 14.1 (2024): 28951.

[110]- Lee, Han Ah, Hye Ah Lee, and Hwi Young Kim. "Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms." Scientific Reports 14.1 (2024): 28951.

[111]- Rao, Guocheng, et al. "Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic." Frontiers in medicine 10 (2023): 1294267.

[112]- Jaffar, Hafiza Madiha, et al. "Impact of silymarin-supplemented cookies on liver enzyme and inflammatory markers in non-alcoholic fatty liver disease patients." Food Science & Nutrition 12.10 (2024): 7273-7286.

[113]- Rinella, Mary E., et al. "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease." Hepatology 77.5 (2023): 1797-1835.

[114]- Besutti, Giulia, et al. "Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review." Liver International 39.8 (2019): 1521-1534.

[115]- Arzehgar, Afrooz, et al. "Non-Alcoholic Fatty Liver Disease Diagnosis with Multi-Group Factors." Healthcare Transformation with Informatics and Artificial Intelligence. IOS Press, 2023. 503-506.

[116]- Kjærgaard, Kristoffer, et al. "Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation." JHEP Reports 6.3 (2024): 100992.

[117]- Jerome, Nirupama Esther, Nancy E. Edwards, and Qinglan Priscilla Ding. "Impact of mediterranean dietary education on symptoms for adults at risk for nonalcoholic fatty liver disease." Gastroenterology Nursing 46.5 (2023): 359-370.

[118]- Fernández-Garibay, Valeria Michelle, and Norberto C. Chavez-Tapia. "The rationale for the aggressive progression of MASLD in patients with type 2 diabetes." Annals of Hepatology 30.1 (2025): 101778.

[119]- Salva-Pastor, Nicolás, et al. "The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider." Gastroenterology and hepatology from bed to bench 12.4 (2019): 267.

[120]- Nadolsky, Karl, et al. "Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey." Annals of Medicine 55.1 (2023): 2211349.

[121]- Mascaró, Catalina M., et al. "Association between stages of hepatic steatosis and physical activity performance in adults with metabolic syndrome: A cross-sectional analysis in FLIPAN Study." Nutrients 14.9 (2022): 1790.

[122]- Newsome, Philip N., et al. "FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study." The lancet Gastroenterology & hepatology 5.4 (2020): 362-373.

[123]- Armandi, Angelo, and Elisabetta Bugianesi. "Extrahepatic outcomes of nonalcoholic fatty liver disease: Cardiovascular diseases." Clinics in Liver Disease 27.2 (2023): 239-250.

[124]- Lazarus, Jeffrey V., et al. "A social media listening study of patients' experiences relating to metabolic dysfunction-associated steatotic liver disease: the LISTEN-MASLD study." Annals of Hepatology 30.1 (2025): 101741.

[125]- Mansour, Asieh, et al. "Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial." Nutrition journal 20.1 (2021): 35.

[126]- Giannotti, Laura, et al. "Coffee Bioactive N-Methylpyridinium: Unveiling Its Antilipogenic Effects by Targeting De Novo Lipogenesis in Human Hepatocytes." Molecular Nutrition & Food Research 68.21 (2024): 2400338.

[127]- Hayat, Umar, et al. "The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies." Annals of hepatology 20 (2021): 100254.

[128]- Laursen, Tea L., et al. "Bariatric surgery in patients with non-alcoholic fatty liver disease-from pathophysiology to clinical effects." World journal of hepatology 11.2 (2019): 138.

[129]- Lassailly, Guillaume, et al. "Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis." Gastroenterology 159.4 (2020): 1290-1301.

[130]- Pais, Raluca, et al. "Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery." Hepatology 76.2 (2022): 456-468.

[131]- Pais, Raluca, et al. "Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery." Hepatology 76.2 (2022): 456-468.

[132]- Armstrong, Matthew J., et al. "Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials." Diabetes, Obesity and Metabolism 27.2 (2025): 710-718.

[133]- Fishman, Jesse, et al. "Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." Journal of Medical Economics 27.1 (2024): 1108-1118.

[134]- Powell, Elizabeth E. "A new treatment and updated clinical practice guidelines for MASLD." Nature Reviews Gastroenterology & Hepatology 22.2 (2025): 88-89.

[135]- Harrison, Stephen A., et al. "A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis." New England Journal of Medicine 390.6 (2024): 497-509.

[136]- Vidal-Cevallos, Paulina, and Norberto Chávez-Tapia. "Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?." Med 5.5 (2024): 375-376.

[137]- Iwaki, Michihiro, et al. "Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol." BMJ open 14.11 (2024): e088862.

[138]- Siddiqui, Mohammad Shadab, et al. "Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis." Clinical Gastroenterology and Hepatology 21.10 (2023): 2597-2605.

[139]- Han, Eugene, et al. "Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial." Diabetes, Obesity & Metabolism 24.4 (2022).

[140]- Hirayama, Kiichi, et al. "Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study." Diabetes, Obesity and Metabolism 27.4 (2025): 2059-2069.

[141]- Shi, Mengran, et al. "Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease." Journal of Diabetes and its Complications 37.10 (2023): 108610.

[142]- Ito, Daisuke, et al. "Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: effect of ipragliflozin in MASLD." Journal of Diabetes Investigation 15.9 (2024): 1220-1230.

[143]- Harrison, Stephen A., et al. "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study." Nature medicine 28.7 (2022): 1432-1438.

[144]- Nagao, Mototsugu, et al. "Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study." Cardiovascular Diabetology 23.1 (2024): 56.

[145]- Koshino, Akihiko, et al. "Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial." Diabetes, Obesity and Metabolism 25.5 (2023): 1413-1418.

[146]- Khaliq, Adil, et al. "The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial." Medicine 103.45 (2024): e40356.

[147]- Ratziu, Vlad, et al. "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study." Journal of Hepatology 76.3 (2022): 506-517.

[148]- Paternostro, Rafael, and Michael Trauner. "Current treatment of non-alcoholic fatty liver disease." Journal of internal medicine 292.2 (2022): 190-204.

[149]- Ratziu, Vlad, et al. "Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH." Journal of hepatology 78.3 (2023): 479-492.

[150]- Alkhouri, Naim, et al. "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial." Journal of hepatology 77.3 (2022): 607-618.

[151]- Alkhouri, Naim, et al. "Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH." Liver International 44.4 (2024): 966-978.

[152]- Liu, Chuanfeng, et al. "Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial." Endocrinology, Diabetes & Metabolism 8.1 (2025): e70021.

[153]- Guo, Wen, et al. "Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial." Diabetes research and clinical practice 170 (2020): 108487.

[154]- Gastaldelli, Amalia, et al. "Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes." Diabetes, Obesity and Metabolism 22.3 (2020): 393-403.

[155]- Parker, Victoria ER, et al. "Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes." Nature metabolism 5.12 (2023): 2086-2093.

[156]- Fan, Yujuan, et al. "Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial." Diabetes, Obesity and Metabolism 26.2 (2024): 772-776.

[157]- Newsome, Philip N., et al. "Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and Design of the Phase 3 ESSENCE trial." Alimentary Pharmacology & Therapeutics 60.11-12 (2024): 1525-1533.

[158]- Harrison, Stephen A., et al. "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study." Journal of Hepatology 82.1 (2025): 7-17.

[159]- Vuppalanchi, Raj, et al. "Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures." Alimentary Pharmacology & Therapeutics 60.1 (2024): 17-32.

[160]- Sanyal, Arun J., et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature medicine 30.7 (2024): 2037-2048.

[161]- Lawitz, Eric J., et al. "Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis." Journal of Hepatology 81.5 (2024): 837-846.

[162]- Abdelmalek, Manal F., et al. "A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis–study design and rationale of HM-TRIA-201 study." Contemporary Clinical Trials 130 (2023): 107176.

[163]- ElKabbany, Zeinab Anwar, et al. "The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: A randomized controlled trial." Diabetes, Obesity and Metabolism 26.12 (2024): 5857-5869.

[164]- Johansson, Lars, et al. "Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes." Diabetes, Obesity and Metabolism 22.7 (2020): 1094-1101.

[165]- Abdelmalek, Manal F., et al. "Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study." Clinical Gastroenterology and Hepatology 22.1 (2024): 113-123.

[166]- Tseng, Chih-Ming Leo, et al. "Population pharmacokinetics and pharmacodynamics of pegozafermin in patients with nonalcoholic steatohepatitis." Clinical Pharmacology & Therapeutics 114.6 (2023): 1323-1331.

[167]- Harrison, Stephen A., et al. "Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial." The Lancet Gastroenterology & Hepatology 8.12 (2023): 1080-1093.

[168]- Rinella, Mary E., et al. "A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis." Hepatology 79.3 (2024): 674-689.

[169]- Athyros, Vasilios G., et al. "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis." The Lancet 376.9756 (2010): 1916-1922.

[170]- Wang, Xuan, et al. "Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial." Diabetes & Metabolic Syndrome: Clinical Research & Reviews 18.9 (2024): 103126.

[171]- Virani, Salim S., et al. "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines." Journal of the American College of Cardiology 82.9 (2023): 833-955.

[172]- Huang, Yuanshe, et al. "Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology." Medicine 101.43 (2022): e31437.

[173]- Ratziu, V., et al. "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial." Nature medicine 27.10 (2021): 1825-1835.

[174]- Baker, Holly. "Selonsertib ineffective in NASH." (2020): 436-436.

[175]- Saxena, Aditi R., et al. "A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes." Diabetes, Obesity and Metabolism 25.4 (2023): 992-1001.